| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | FUROSCIX ReadyFlow™ Autoinjector (SCP-111) Edema in adult patients with chronic heart failure (CHF), chronic kidney disease (CKD) | PDUFA | — | Subscribe to access the data. | Medical Devices | Cardiovascular System | |
PDUFA Date example | FUROSCIX ReadyFlow™ Autoinjector (SCP-111) Edema in adult patients with chronic heart failure (CHF), chronic kidney disease (CKD) | PDUFA | — | Subscribe to access the data. | Medical Devices | Cardiovascular System | |
PDUFA Date example | FUROSCIX ReadyFlow™ Autoinjector (SCP-111) Edema in adult patients with chronic heart failure (CHF), chronic kidney disease (CKD) | PDUFA | — | Subscribe to access the data. | Medical Devices | Cardiovascular System |
Recent Updates
Recently added Catalysts
MannKind Corporation$4.09
-0.06 (-1.55%)
B 77Pipeline Score Undervalued Pharma · Commercial
Market Cap
1.04 B
EPS
-0.08
P/E Ratio
-
Value Trade
11.87 M
SEC Financials
Q1 2026Dilution Risk
Revenue
90.17 M
R&D Expenses
17.23 M
Operating CF
-5.37 M
Total Assets
744.40 M
Total Liabilities
803.60 M
Equity
-59.20 M
D/E Ratio
12,345
5.96 %
Week
22.91 %
1 Month
-38.66 %
3 Month
-31.85 %
6 Month
-21.76 %
5 Year
-95.64 %
All Time
Cash Data
Cash Position
133.86 M
Monthly Burn
1.79 M
Runway
73 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
4.25 M
52 Week Range
2.23 - 6.51
% held by Insiders
4.67 %
% held by Institutions
56.61 %
Enterprise Value
1.35 B
Total Shares
308.88 M
Short %
9.44 %
Float Shares
277.38 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for MannKind Corporation
595Total events
12Upcoming
130Tier-1 (high impact)
2013 – 2026Coverage
Upcoming catalysts 12
Dec 31, 2026
T2Milestone Payment
Potential $50M milestone if trailing 12-month net sales of Tyvaso DPI reach $1.9B by December 31, 2026
TBD
T2First Patient Dosed
Planned Phase 1 study in healthy volunteers to assess dosing and PK comparability
TBD
T1Partnership / License
Preclinical studies for new dry powder inhalation therapy under expanded collaboration with United Therapeutics
Event history 583
Q3 2026
◆Topline ReadoutClinical Data
Phase 1b INFLO-1 data readout anticipated
idiopathic pulmonary fibrosissource ↗
Q3 2026
◆Topline ReadoutMNKD-201Clinical Data
Topline data from Phase 1b INFLO-1 trial of MNKD-201
idiopathic pulmonary fibrosis (IPF)source ↗
Jun 23, 2026
▲Breakthrough Therapy DesignationDesignation
Breakthrough T1D grant awarded to support INHALE-1ST trial of Afrezza
type 1 diabetessource ↗
Jun 23, 2026
▲Enrollment CompleteAfrezzaApprovedTrial
Completed enrollment of pilot phase of INHALE-1ST trial
type 1 diabetessource ↗
Jun 8, 2026
◆Poster PresentationAfrezzaApprovedPresentation
Poster: Subcutaneous Furosemide Use for Fluid Overload in Persons Living with Diabetes Mellitus
diabetessource ↗
Jun 7, 2026
◆Oral PresentationAfrezzaApprovedPresentation
Late-breaking comparative data vs. rapid-acting insulin analogs at ADA 2026
diabetessource ↗
Jun 7, 2026
◆Poster PresentationAfrezzaApprovedPresentation
Poster: Inhaled Technosphere Insulin Compared with Rapid-Acting Analog Insulin in Gestational Diabetes
gestational diabetessource ↗
Jun 6, 2026
◆Poster PresentationAfrezzaApprovedPresentation
Poster: Efficacy and Safety of Inhaled Technosphere Insulin vs. Rapid-Acting Analog in Youth with HbA1c ≤9.5%: Subgroup Analysis from INHALE-1
diabetessource ↗
Jun 3, 2026
Jun 3, 2026
▲Enrollment CompleteTrial
Completion of patient randomization in Phase 1b INFLO-1 study
idiopathic pulmonary fibrosissource ↗
Jun 3, 2026
▲First Patient DosedTrial
First patient enrolled in global Phase 2 INFLO-2 trial
idiopathic pulmonary fibrosissource ↗
May 29, 2026
▲FDA ApprovalAfrezzaApprovedFDA Decision
FDA approval of Afrezza for pediatric use
type 1 and type 2 diabetes in children and adolescents aged 6 and oldersource ↗
Drug Pipeline Intelligence
B77
Pipeline Score $9.5B
Pipeline ValueUndervalued
Valuation Signal20
Drugs Scored15.0x
rNPV / MCap Top 96%
Micro Cap (rank 37 of 911)
Percentile RankMannKind Corporation holds a solid B-grade pipeline (77/100), with $23.8B risk-adjusted pipeline value, led by Technosphere Insulin in Type 1 Diabetes Mellitus (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Technosphere Insulin Small molecule | Type 1 Diabetes Mellitus | Phase 3 | NCT01544881 | 53% | $13.6B | COMPLETED | 635 | - | - | Jan 1, 2013 | MODERATE_RISK | Jan 25, 2013 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Afrezza Breakthrough | diabetes in pediatric patients | — | 2026-05-27 | 26-week A1c changes in CGM metrics; HbA1c <8% at 26 weeks | MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza ) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems Read More | |
Afrezza Breakthrough | diabetes in pediatric patients | — | 2026-05-27 | 26-week A1c changes in CGM metrics; HbA1c <8% at 26 weeks | MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza ) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems Read More | |
Afrezza Breakthrough | diabetes in pediatric patients | — | 2026-05-27 | 26-week A1c changes in CGM metrics; HbA1c <8% at 26 weeks | MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza ) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MNKD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MNKD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MNKDMannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
MannKind Corporation has received a grant from Breakthrough T1D to support the INHALE-1ST clinical trial, which evaluates the use of Afrezza in pediatric patients newly diagnosed with type 1 diabetes. This study aims to assess the safety and efficacy of Afrezza combined with basal insulin in youth aged 10 to under 18. The collaboration emphasizes the importance of advancing inhaled insulin options for pediatric diabetes care.
Read more →MNKDMannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
MannKind Corporation has announced significant milestones in the development of nintedanib DPI for idiopathic pulmonary fibrosis (IPF), including the completion of patient randomization in the Phase 1b INFLO-1 study and the enrollment of the first patient in the Phase 2 INFLO-2 trial. Data from the INFLO-1 study is expected in Q3 2026, which will assess safety, tolerability, and pharmacokinetics. The Phase 2 trial aims to evaluate efficacy and safety across approximately 210 participants globally.
Read more →MNKD▲ +5.3%on this newsshared move
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
MannKind Corporation has received FDA approval for Afrezza, the first inhaled mealtime insulin for children and adolescents aged 6 and older with diabetes. This innovative treatment allows for dosing at the start of meals, providing a flexible, needle-free option for managing diabetes. The approval is based on extensive clinical data, including the Phase 3 INHALE-1 study, and aims to enhance pediatric diabetes care.
Read more →MNKDMannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
MannKind Corporation announced a conference call to discuss the FDA's recent approval of Afrezza for children and adolescents aged 6 and older with diabetes. The call will feature CEO Michael Castagna and Senior VP Kevin Kaiserman. The event is scheduled for May 29, 2026, at 4:30 p.m. Eastern.
Read more →MNKDMannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza ) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
MannKind Corporation is set to present new analyses on its inhaled insulin Afrezza at the ADA 2026 Scientific Sessions. The findings will explore Afrezza's use in pediatric patients, pregnant women, and its compatibility with automated insulin delivery systems. The data aims to support the upcoming FDA target action date of May 29, 2026, for Afrezza's use among children and adolescents living with diabetes. The company is optimistic about the potential approval, claiming it would bring the first needle-free insulin option to pediatric patients in over a century.
Read more →MNKDMannKind to Present at Jefferies Global Healthcare Conference
MannKind Corporation announced that its CEO, Michael Castagna, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3. The event will be accessible via a live audio webcast on the company's website, with recorded versions available for 90 days post-conference. MannKind is dedicated to developing treatments for chronic diseases.
Read more →MNKD▲ +24.5%on this news
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
MannKind Corporation has announced the development of a dry powder inhalation formulation of ralinepag in collaboration with United Therapeutics. The program aims to address pulmonary hypertension and fibrotic lung diseases. United Therapeutics has committed additional funding to support this initiative, which could yield significant milestone payments for MannKind. The formulation is expected to enter clinical studies soon.
Read more →MNKD▲ +24.5%on this newsshared move
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update  Q1 updates:  Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025  Built out launch infrastructure and aligned fie
MannKind Corporation reported its financial results for Q1 2026, showing total revenues of $90.2 million, a 15% increase from the previous year. The report highlighted advancements in various product lines, including upcoming PDUFA dates for Afrezza and Furoscix. However, the company faced challenges with rising operating expenses and lower gross margins as a result of new product integrations. CEO Michael Castagna emphasized that 2026 is poised to be a catalyst-rich year for the firm.
Read more →MNKDMannKind to Report First Quarter 2026 Financial Results on May 6, 2026
MannKind Corporation announced it will report its first quarter 2026 financial results on May 6, 2026, after the market closes. A webcast will follow at 4:30 PM Eastern Time to discuss the financial outcomes and provide a business update. The event can be accessed via MannKind's investor relations website, where a replay will also be available for 90 days post-call. The company focuses on developing treatments for cardiometabolic and orphan lung diseases, addressing significant unmet medical needs.
Read more →MNKDMannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
MannKind Corporation announced it will present new clinical data on Afrezza at the ATTD 2026 conference. The presentations will cover real-world dosing patterns and glucose management strategies for both adults and pediatric patients with type 1 diabetes. The FDA's review of Afrezza for children and adolescents is ongoing, with a target action date set for May 29, 2026.
Read more →MNKDMannKind Announces Settlement of Convertible Senior Notes
MannKind Corporation announced the successful settlement of $36.3 million in 2.50% convertible senior notes, all of which were converted prior to the maturity date. The settlement, completed on March 4, 2026, included $35.5 million in cash and the issuance of 569,023 shares of common stock. This step reflects MannKind's continued commitment to its financial obligations and its ongoing focus on addressing critical healthcare needs in cardiometabolic and orphan lung diseases.
Read more →MNKDMannKind to Participate in Upcoming Investor Conferences
MannKind Corporation will participate in two upcoming investor conferences in Miami. CEO Michael Castagna and CFO Chris Prentiss will engage in fireside chats and one-on-one meetings with investors. The conferences are scheduled for March 10 and March 11, 2026, and will be accessible via live audio webcasts on MannKind's website.
Read more →MNKD▼ -7.4%on this news
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
MannKind Corporation reported its fourth quarter and full year 2025 financial results, highlighting strong revenue growth driven by its commercial products, particularly Furoscix and Afrezza. The company anticipates a catalyst-rich 2026 with two FDA decisions and upcoming clinical trial data. CEO Michael Castagna expressed confidence in the company's position to deliver long-term value.
Read more →MNKDMannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
MannKind Corporation has announced that its CEO, Michael Castagna, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The presentation will include business updates and insights into the company's focus on developing treatments for chronic diseases, such as diabetes and pulmonary hypertension. The event highlights MannKind's commitment to innovative therapies that address serious medical needs.
Read more →MNKDMannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
MannKind Corporation will announce its fourth quarter and full year 2025 financial results on February 26, 2026. A webcast will follow at 9:00 a.m. ET for a review of the results and a business update. The company focuses on innovative treatments for chronic diseases, including diabetes and pulmonary hypertension.
Read more →MNKDMannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
MannKind Corporation has announced the enrollment of the first patient in the INHALE-1ST study, which evaluates the use of Afrezza, an inhaled insulin, in pediatric patients newly diagnosed with type 1 diabetes. The study aims to assess the safety and efficacy of Afrezza in combination with basal insulin, potentially easing the burden of daily insulin injections. The trial will involve approximately 100 participants across multiple sites in the U.S. and is part of a broader effort to improve diabetes management in children.
Read more →MNKDMannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
MannKind Corporation announced FDA approval for an updated prescribing label for Afrezza, which provides clearer starting dose guidance for patients switching from multiple daily injections or insulin pumps. This update aims to facilitate a smoother transition to inhaled insulin and is supported by clinical data demonstrating improved glucose outcomes. However, the label also highlights potential risks, including acute bronchospasm and hypoglycemia.
Read more →MNKDMannKind Provides Business Updates and 2026 Growth Drivers
MannKind Corporation announced business updates and growth drivers for 2026, highlighting major milestones achieved in 2025. Among the key developments is the potential FDA decision regarding Afrezza's label update, aiming to provide a new insulin option for young patients. MannKind also plans to pursue a supplemental drug application for the FUROSCIX ReadyFlow Autoinjector. The company's leadership expressed optimism about the future, underpinning their commitment to advancing innovative treatments for chronic diseases.
Read more →MNKDMannKind Shares FUROSCIX Business Updates
MannKind Corporation has received FDA approval for the FUROSCIX On-body Infusor, extending its use to pediatric patients weighing 43 kg or more. Additionally, the company has been granted five new patents for the FUROSCIX ReadyFlow Autoinjector, which is currently under FDA review. The ReadyFlow Autoinjector aims to provide a rapid, subcutaneous delivery method for treating fluid overload in patients with chronic heart failure or chronic kidney disease. If approved, it may substantially enhance patient care by allowing treatment at home, potentially lessening hospital visits and healthcare costs.
Read more →MNKDMannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
MannKind Corporation announced that the FDA has accepted its supplemental new drug application for the FUROSCIX ReadyFlow Autoinjector, designed to deliver subcutaneous furosemide injections in under 10 seconds. This device, aimed at adults with chronic heart failure or chronic kidney disease, could transform patient care by allowing at-home treatment for fluid buildup episodes. The application awaits a decision by the FDA, with a target action date set for July 26, 2026. Positive results from clinical studies support this new option for patients.
Read more →MNKDMannKind to Present at the Jefferies Global Healthcare Conference
MannKind Corporation announced that CEO Michael Castagna and CFO Chris Prentiss will present at the Jefferies Global Healthcare Conference on November 19. The presentation will include updates on the company's innovative treatments for chronic diseases. A live audio webcast will be available, along with recorded versions for later access.
Read more →MNKDMannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
MannKind Corporation has announced the discontinuation of its Phase 3 ICoN-1 trial for MNKD-101, a nebulized clofazimine treatment for NTM lung disease, due to futility. An analysis revealed no sputum culture conversions among the first 46 participants. The independent Data Safety Monitoring Board confirmed the decision, noting no safety concerns. MannKind is now focusing on its MNKD-102 formulation, which is progressing toward Phase 1 development.
Read more →MNKD▼ -5.9%on this newsshared move
MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
MannKind Corporation has announced the launch of the Centennial Al Mann Scholarship to commemorate the 100th birthday of its founder, Alfred E. Mann. The program will distribute $100,000 in scholarships to at least 10 young adults living with diabetes, supporting their pursuit of higher education in life sciences. The initiative reflects Mann's legacy of innovation and philanthropy.
Read more →MNKD▲ +10.6%on this newsshared move
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
MannKind Corporation reported a 17% increase in total revenues for Q3 2025, driven by higher sales of Afrezza and Tyvaso DPI. The acquisition of scPharmaceuticals is expected to enhance their commercial capabilities. Additionally, the FDA has accepted the pediatric sBLA for Afrezza, marking a significant regulatory milestone. However, there was a noted decrease in revenue from V-Go due to lower demand.
Read more →MNKDMannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
MannKind Corporation will release its third quarter 2025 financial results on November 5, 2025, before the market opens. A webcast will follow at 9 a.m. ET to discuss the results and provide a business update. The company focuses on innovative treatments for chronic diseases, including diabetes and pulmonary hypertension.
Read more →MNKDMannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
MannKind Corporation announced that the FDA has accepted its supplemental biologics license application for Afrezza, an inhaled insulin, for children and adolescents aged 4-17 with diabetes. The application is based on the Phase 3 INHALE-1 study results, which compared Afrezza with multiple daily injections. A PDUFA target action date is set for May 29, 2026, with full study results to be presented at an upcoming conference.
Read more →MNKDMannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
MannKind Corporation has successfully completed its acquisition of scPharmaceuticals, which is expected to diversify and accelerate its revenue growth in cardiometabolic care. This acquisition enhances MannKind’s commercial capabilities and positions it to expand FUROSCIX’s reach in treating chronic heart failure. The tender offer saw strong participation, with approximately 73.47% of scPharmaceuticals' shares tendered. MannKind aims to leverage its expertise in endocrinology along with scPharmaceuticals' capabilities to foster growth and innovation in chronic disease therapies.
Read more →MNKDMannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
MannKind Corporation has appointed Dr. Ajay Ahuja as the new Chief Medical Officer. Dr. Ahuja, who has over two decades of experience in the biopharmaceutical industry, will report directly to CEO Michael Castagna. His expertise in medical affairs and cardiometabolic areas is expected to enhance MannKind's efforts in developing innovative therapies for endocrine and orphan lung diseases.
Read more →MNKDMannKind to Present at Upcoming Investor Conferences
MannKind Corporation announced its participation in several upcoming investor conferences, where CEO Michael Castagna and CFO Chris Prentiss will provide updates. The conferences include the Wells Fargo Health Care Conference, Cantor Global Healthcare Conference, H.C. Wainwright 27th Annual Global Investment Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference. Live audio webcasts and recorded versions will be available on their website.
Read more →MNKD▲ +11.1%on this news· ran to +41% by day 3shared move
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
MannKind Corporation has announced an expansion of its collaboration with United Therapeutics to develop a second dry powder inhalation therapy. This follows the success of Tyvaso DPI, which received FDA approval in May 2022. MannKind will formulate the new investigational molecule, while United Therapeutics will handle its preclinical and clinical development. The agreement includes an upfront payment and potential milestone payments.
Read more →MNKD▼ -5.1%on this newsshared move
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
MannKind Corporation announced its acquisition of scPharmaceuticals, aiming to enhance its revenue growth in the cardiometabolic sector. The deal involves an upfront cash payment of $5.35 per share, representing a significant premium, and additional contingent value rights based on regulatory milestones. This strategic move is set to diversify MannKind's portfolio and strengthen its market presence while tapping into a $10 billion addressable market for cardiorenal treatments. The acquisition aligns with MannKind's commitment to delivering patient-centric therapies and is expected to accelerate its growth trajectory.
Read more →MNKDMannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases Acquisition expected to diversify and accelerate doub
MannKind Corporation has entered into a definitive merger agreement to acquire scPharmaceuticals, a move aimed at enhancing its portfolio in cardiometabolic diseases. The acquisition, valued at approximately $360 million, is expected to close in the fourth quarter of 2025, subject to regulatory approvals. This strategic expansion aligns with MannKind's commitment to patient-centered care, particularly in cardiometabolic and lung disease sectors. scPharmaceuticals' FDA-approved product, FUROSCIX, is anticipated to significantly improve treatment efficiencies in chronic heart failure and chronic kidney disease.
Read more →MNKD▼ -13.2%on this news
MANNKIND CORPORATION REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference call today at 9:00 am ET • 2Q 2025 revenues of $76.5M, +6% v. 2Q 2024 • YTD 2025 revenues of $154.9
MannKind Corporation reported its financial results for the second quarter of 2025, highlighting a revenue increase of 6% year-over-year, with total revenues reaching $76.5 million. The company also noted robust progress in clinical trials, particularly with MNKD-101 and the submission of a supplemental Biologics License Application for Afrezza targeting pediatric patients. Despite the overall positive financial performance, there were significant increases in operational expenses and losses due to foreign currency transactions. The conference call scheduled for today will likely provide further insights into the company's strategic direction.
Read more →MNKD▼ -13.2%on this news
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
MannKind Corporation has entered into a strategic financing agreement with Blackstone, providing up to $500 million in non-dilutive funding. The agreement includes a $75 million initial term loan and potential additional funds to support MannKind's growth strategies, particularly the launch of the pediatric indication for Afrezza. Blackstone's partnership is expected to enhance MannKind's commercialization efforts, although there are risks related to obtaining the delayed draw term loans and potential regulatory delays.
Read more →MNKDMannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025
MannKind Corporation has announced that it will release its second quarter 2025 financial results on August 6, 2025, before the market opens. A webcast is scheduled to begin at 9:00 a.m. Eastern Time, where the company will discuss its results and provide a business update. MannKind specializes in developing inhaled therapeutic products aimed at addressing conditions such as diabetes and pulmonary diseases, showcasing its commitment to innovative healthcare solutions.
Read more →MNKDMannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza ) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
MannKind Corporation is set to showcase new data from its inhaled insulin product, Afrezza, at the American Diabetes Association's 85th Scientific Sessions in Chicago from June 20-23. Dr. Michael J. Haller will present the results from the pediatric clinical trial INHALE-1, focusing on the treatment's efficacy and safety in children and adolescents with Type 1 diabetes. Additionally, MannKind expects to release topline results from the full pediatric data set by the second quarter of 2025 and plans to submit a Supplemental Biologics License Application in mid-2025 for a potential pediatric indication.
Read more →MNKDMANNKIND CORPORATION REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference call to provide corporate updates today at 9:00 am ET • 1Q 2025 revenues of $78M, +18% v. 1Q 2024 •
MannKind Corporation reported its financial results for the first quarter of 2025, showcasing a significant increase in revenue of 18% year-over-year, amounting to $78 million. The company's net income also saw a rise of 24%, reaching $13 million. Highlights include ongoing developments in clinical trials for both MNKD-101 and MNKD-201, with expectations for a supplemental BLA filing for Afrezza in pediatric patients by mid-2025. The positive financial growth reflects robust demand for their products, particularly Afrezza and Tyvaso DPI.
Read more →MNKDMannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
MannKind Corporation has announced that it will release its first quarter 2025 financial results before market open on May 8, 2025. A conference call will follow at 9:00 a.m. Eastern Time, featuring CEO Michael Castagna and CFO Chris Prentiss. The event will provide insights into the financial performance of the company and updates regarding its business operations. The webcast will be accessible through MannKind's website, with a replay available for approximately 90 days.
Read more →MNKDMannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
MannKind Corporation has announced its partnership with Juncos Hollinger Racing driver Conor Daly for the 2025 NTT INDYCAR Series season. Daly, who has type 1 diabetes, will race with a car featuring an attention-grabbing 'Tired of Pricks?' livery, aimed at promoting diabetes awareness. MannKind will serve as a primary sponsor during several races, including the Acura Grand Prix of Long Beach. The collaboration emphasizes MannKind's commitment to innovative treatments for diabetes and showcases the drive for broader public engagement through motorsport.
Read more →MNKDMannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza at the ATTD Conference, March 19-22
MannKind Corporation is set to present data from its studies of Afrezza, an inhaled insulin, at the ATTD Conference in March 2025. The presentations will include findings from the INHALE-1 pediatric and INHALE-3 adult studies, both indicating favorable results for the inhaled treatment. MannKind anticipates filing a supplemental New Drug Application for Afrezza in the pediatric population in 2025. Safety concerns exist regarding acute bronchospasm in patients with chronic lung conditions related to the use of Afrezza.
Read more →MNKDMANNKIND CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference call to provide corporate updates today at 4:30 pm ET • 2024 revenues of $286M, + 43% v. 202
MannKind Corporation reports robust financial results for 2024, with revenues reaching $286 million, up 43% from the previous year. The company achieved a net income of $28 million and made significant progress in clinical trials, particularly for the pediatric use of Afrezza. Additionally, operational updates indicate advancements in their orphan lung disease programs. However, challenges persist with declining demand for the V-Go product and rising operating expenses.
Read more →MNKDMannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
MannKind Corporation is set to release its financial results for the fourth quarter and full year of 2024 on February 26, 2025. A conference call will be held at 4:30 p.m. Eastern Time, featuring CEO Michael Castagna and CFO Chris Prentiss to discuss these results and provide a business update. The company specializes in developing inhaled therapeutic products targeted at treating various serious medical conditions. An accessible link for the webcast will be available on MannKind’s website.
Read more →MNKDMannKind Expands Executive Leadership Team
MannKind Corporation has announced the appointment of Dominic Marasco, RPh, as President of the Endocrine Business Unit, effective January 6, 2025. Marasco brings over 25 years of experience in the biopharmaceutical industry, having held leadership roles in several prominent companies. His background in driving strategic growth is expected to contribute significantly to MannKind's ongoing projects, particularly in the development of their inhaled therapeutic products. The company continues to emphasize its commitment to innovation in endocrine care.
Read more →MNKDMannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
MannKind Corporation has entered into exchange agreements to convert approximately $194 million of its Convertible Senior Notes into stock and cash. This deal will significantly reduce MannKind's outstanding debt by 84% and lower its annual interest expenses by $4.9 million. Following the transaction, the company expects to have more than $180 million in cash and will have fewer shares reserved for conversion, thus mitigating potential dilution. The transaction is set to close in two phases before the end of December 2024.
Read more →MNKDMannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza )
MannKind Corporation announced positive six-month results from its Phase 3 INHALE-1 study of Afrezza, an inhaled insulin, for children aged 4-17. The study demonstrated that Afrezza is non-inferior to traditional multiple daily injections in managing diabetes, thus marking a significant advancement in treatment options. MannKind plans to engage with the FDA for a potential supplemental new drug application in the first half of 2025, aiming to expand the use of inhaled insulin among pediatric patients. The study's assessment also indicated no notable safety concerns regarding lung function.
Read more →MNKDMANNKIND CORPORATION REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call to Begin Today at 4:30 p.m. (ET) • 3Q 2024 Total revenues of $70M; +37% vs. 3Q 2023 • YTD 2024
MannKind Corporation reported strong financial results for the third quarter of 2024, with a total revenue of $70 million, reflecting a 37% increase compared to the same period last year. The company also achieved a YTD net income of $20 million and notable progress in clinical trials, including a successful Phase 1 trial for MNKD-201. However, there were some challenges, such as a decrease in revenue for the V-Go product due to lower demand, and selling expenses that reflected a decline relating to a sales force restructuring. Overall, MannKind continues to demonstrate significant growth and advancements in its product pipeline.
Read more →MNKDMannKind to Present at 2024 UBS Healthcare Conference
MannKind Corporation (MNKD) has announced that its CEO and CFO will present updates at the 2024 UBS Healthcare Conference in California. The presentation, scheduled for November 12, will include insights into the company's focus on developing innovative inhaled therapies for endocrine and orphan lung diseases. A live audio webcast of the session will be available, as well as a recorded version for later viewing. The event highlights MannKind's commitment to addressing significant medical needs through advanced therapeutic products.
Read more →MNKDMannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
MannKind Corporation has successfully completed a Phase 1 trial for nintedanib DPI, demonstrating the safety and tolerability of the product in healthy volunteers. Notably, participants did not experience common adverse effects typically seen with oral nintedanib. The company plans to meet with the FDA in the first half of 2025 to discuss advancing the development of this inhaled therapy for pulmonary fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). These findings could provide new treatment options for patients with IPF, which has limited existing therapies.
Read more →MNKDMannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
MannKind Corporation has announced that it will release its third quarter 2024 financial results on November 7, 2024. A conference call will follow the release, hosted by CEO Michael Castagna and CFO Chris Prentiss, discussing the results and providing a business update. The company specializes in developing and commercializing inhaled therapies aimed at addressing serious health issues related to endocrine and orphan lung diseases. The virtual event will be accessible via their website, with a replay available for 90 days. This initiative emphasizes MannKind's commitment to transparency with its stakeholders.
Read more →MNKDMannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
MannKind Corporation has announced that it received clearance from Japan’s PMDA to start its Phase 3 clinical trial (ICoN-1) of Clofazimine Inhalation Suspension for treating Nontuberculous Mycobacterial lung disease. This study is part of a broader global initiative, with clearances also obtained from health authorities in South Korea and Australia, and Taiwan expected by late 2024. The trial aims to enroll around 230 participants and evaluate the treatment's efficacy and safety.
Read more →MNKDMannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
MannKind Corporation will present at the 2024 Cantor Fitzgerald Global Healthcare Conference, with CFO Chris Prentiss and Dr. Wasim Fares discussing updates on the company's therapeutic products. The fireside chat is scheduled for September 18 at 1:20 p.m. Eastern Time and will be accessible through a live audio webcast. MannKind is known for its innovative inhaled therapies targeting endocrine and orphan lung diseases.
Read more →MNKDMannKind to Present at Upcoming Conferences
MannKind Corporation, focused on inhaled therapeutic products, is set to present at three upcoming investor conferences. CEO Michael Castagna and CFO Chris Prentiss will share important updates, providing opportunities for investors to gain insights into the company's developments. The conferences include the Wells Fargo Healthcare Conference, the Morgan Stanley Global Healthcare Conference, and the H.C. Wainwright Investment Conference, all taking place in September 2024. Live audio webcasts will be available on their website, ensuring accessibility to their presentations.
Read more →MNKDMANNKIND CORPORATION REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 9:00 a.m. (ET) • 2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023 •
MannKind Corporation reported its financial results for the second quarter of 2024, highlighting total revenues of $72 million, up 49% from the same quarter in the previous year. The company marked its ninth consecutive quarter of revenue growth and advanced two orphan lung programs into human studies. However, net revenue from its V-Go product saw a decline, reflecting lower demand. Additionally, the company faced increased research and development expenses, contributing to a loss during the quarter.
Read more →MNKDMannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
MannKind Corporation has launched an educational website, LearnAboutNTM.com, to raise awareness of nontuberculous mycobacterial (NTM) lung disease. The initiative coincides with World NTM Awareness Day on August 4 and aims to support patients and caregivers in understanding the disease. The site is intended to promote early detection and provide vital resources, as NTM lung disease is often undiagnosed for years. MannKind's commitment to addressing such rare diseases reflects its broader mission to improve patient health outcomes through innovative therapeutic solutions.
Read more →MNKDMannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
MannKind Corporation announced it will report its second quarter 2024 financial results before the market opens on August 7, 2024. A press release detailing these results will be available one hour prior to the conference call, which will begin at 9:00 a.m. ET. The call will be led by CEO Michael Castagna and CFO Chris Prentiss, providing insights into the company's financial performance and strategy. MannKind focuses on developing innovative inhaled therapies for serious medical conditions, emphasizing patient access to effective treatments.
Read more →MNKDMannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
MannKind Corporation has announced a strategic partnership with Pulmatrix to expand its research and development presence in the Boston area. The non-cash agreement involves the licensing of iSPERSE technology from Pulmatrix in exchange for MannKind's Cricket inhaler for migraine treatments. This collaboration aims to enhance MannKind's capabilities in developing innovative inhalation therapies, particularly for orphan lung diseases, while also transitioning staffing from Marlborough to the new Bedford facility. The agreement is expected to finalize by July 2024.
Read more →MNKDMANNKIND CORPORATION REPORTS 2024 FIRST QUARTER FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 5:00 p.m. (ET) • 1Q 2024 Total revenues of $66M; +63% vs. 1Q 2023 •
MannKind Corporation reported a robust financial performance for the first quarter of 2024 with total revenues reaching $66 million, marking a 63% increase year-over-year. The company's net income also saw improvements, driven by strong growth in royalties and collaborations. Additionally, the firm secured FDA Fast Track designation for MNKD-101, which could expedite its development. However, net revenue from V-Go experienced a decline, and R&D expenses rose significantly due to increased activities. The company continues to demonstrate strong operational trends with increased gross margins.
Read more →MNKDMannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
MannKind Corporation announced that the U.S. FDA has granted Fast Track designation to Clofazimine Inhalation Suspension for treating nontuberculous mycobacterial lung disease. This designation is designed to expedite the development and review process for treatments addressing serious conditions. MannKind plans to initiate a clinical trial (ICoN-1) for the investigational product in June 2024, both in the U.S. and internationally. The treatment is especially aimed at patients with refractory cases of this disease, which is a significant global health concern.
Read more →MNKD▲ +5.6%on this newsshared move
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
MannKind Corporation will release its financial results for the first quarter of 2024 on May 8, 2024. The management will host a conference call at 5:00 PM Eastern Time to discuss these results and provide corporate updates. Interested stakeholders can listen live via the company's website. MannKind continues to focus on developing products for endocrine and orphan lung diseases.
Read more →MNKDMannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
MannKind Corporation announced it will proceed with a Phase 1 study of nintedanib DPI (MNKD-201) aimed at treating pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis. The study is set to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers, with enrollment of the first participant expected in June 2024. This initiative follows the company's Phase 3 study of Clofazimine Inhalation Suspension. The Phase 1 trial's results are anticipated later this year and will inform subsequent studies in affected patient populations.
Read more →MNKDMannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
MannKind Corporation has received clearance from the U.S. FDA for its Investigational New Drug application for MNKD-101, a Clofazimine Inhalation Suspension, allowing the company to initiate a Phase 3 study for the treatment of nontuberculous mycobacterial (NTM) lung disease. The trial aims to evaluate the efficacy and safety of the treatment when added to standard therapy in adults with refractory NTM lung disease. This development is positioned to meet a significant unmet medical need, particularly as NTM lung disease cases are on the rise globally. The Phase 3 study is expected to commence by the end of Q2 2024 in the U.S. and in the latter half of 2024 internationally.
Read more →MNKDMannKind Repays Certain Debt Obligations
MannKind Corporation (MNKD) has successfully repaid its debts, including approximately $31.6 million to MidCap Financial Trust and $8.9 million to Mann Group LLC in exchange for shares. This repayment eliminates its most expensive debt and releases all associated assets from security interests. MannKind has also improved its financial position, reducing total debt by nearly $41.8 million since the end of 2023. The CEO expressed confidence in the undervalue of their stock and emphasized future dilution reduction.
Read more →MNKDMannKind Announces CFO Transition
MannKind Corporation has announced the retirement of CFO Steven B. Binder, effective April 22, 2024, while he transitions to a role as Executive Vice President, Special Projects until the end of the year. Christopher Prentiss has been appointed as the new Chief Financial Officer, effective the same date. CEO Michael Castagna expressed excitement for Prentiss's joining the company, emphasizing the need for fiscal discipline as MannKind continues to grow. The leadership transition is aimed at building on the company’s recent financial successes and achieving future milestones.
Read more →MNKDMannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
MannKind Corporation announced that new clinical data from its INHALE-3 study will be presented at the upcoming ATTD conference in Florence. This Phase 4 U.S. clinical trial evaluates inhaled insulin compared to standard care in individuals with Type 1 diabetes. During the presentation, findings will discuss post-prandial glucose levels, glucose outcomes, and hypoglycemia rates. Dr. Irl B. Hirsch will lead the session on March 8, 2024, detailing the results of a standardized meal challenge.
Read more →MNKDMannKind Corporation Announces Participation at Upcoming Conferences
MannKind Corporation (Nasdaq: MNKD) announced its participation in several upcoming conferences, including the Leerink Partners Global Biopharma Conference and the Oppenheimer Annual Healthcare MedTech & Services Conference. The company aims to showcase its innovative therapeutic products and devices targeted at endocrine and orphan lung diseases. With a commitment to addressing serious medical needs, MannKind continues to focus on enhancing patient health through its unique inhalation technologies and formulations.
Read more →MNKD▲ +5.6%on this news· ran to +26% by day 3
MANNKIND CORPORATION REPORTS 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 5:00 p.m. (ET) • 2023 Total revenues of $199M; +99% vs. 2022
MannKind Corporation has reported significant financial growth for 2023, with total revenues reaching $199 million, representing a 99% increase from the previous year. In the fourth quarter, the company reported net income of $1 million and demonstrated strong cash reserves of $302 million. The results reflect higher product demand for Afrezza and growth in collaborations, despite a decrease in V-Go revenues. Additionally, the company is planning to advance its clinical programs, moving MNKD-101 into phase 3 and MNKD-201 into phase 1 soon.
Read more →MNKDMannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
MannKind Corporation will host a conference call on February 27, 2024, to discuss its financial results for the fourth quarter and full year of 2023. CEO Michael Castagna and CFO Steven Binder will present the results and offer corporate updates. The call is accessible to the public via the company's website, reflecting MannKind's commitment to engagement with its investors and stakeholders.
Read more →MNKDMannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza
MannKind Corporation has completed its enrollment goal for the INHALE-1 trial, which focuses on the efficacy and safety of its inhaled insulin, Afrezza, in pediatric patients with type 1 and type 2 diabetes. The study, which enrolled 305 participants, aims to provide more treatment options for children and adolescents, and primary endpoint results are expected in the fourth quarter of 2024. Following the analysis, data dissemination and potential FDA submission are anticipated in 2025.
Read more →MNKD▲ +7.7%on this news
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
MannKind Corporation recently entered into a royalty purchase agreement with Sagard Healthcare, wherein Sagard acquired a 1% royalty on net sales of Tyvaso DPI for a total of up to $200 million. This includes an immediate $150 million payment and an additional milestone payment that could reach $50 million based on future sales performance. Tyvaso DPI, approved for treating pulmonary arterial hypertension, is marketed by United Therapeutics. MannKind retains a 9% royalty on sales beyond the purchased 1% and is set to report further details in an upcoming conference call.
Read more →MNKDMannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
MannKind Corporation will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, in San Francisco. CEO Michael Castagna will provide insights into the company's developments in inhaled therapeutic products. The event aims to highlight MannKind's commitment to improving treatment for patients with various lung diseases. Interested parties can listen live or access a replay of the presentation on the company's website.
Read more →MNKDPURCHASE AND SALE AGREEMENT dated as of
MannKind Corporation has entered into a Purchase and Sale Agreement with Sagard Healthcare Partners Funding Borrower SPE 2, LP, dated December 27, 2023. The agreement outlines the terms for the sale of certain assets and includes various representations, warranties, and covenants from both parties. It specifies the defined terms, purchase price, and closing procedures for the transaction. Further details stipulate obligations related to royalties and compliance with applicable laws.
Read more →MNKDCERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. SEVENTH
MannKind Corporation and Amphastar Pharmaceuticals have executed a Seventh Amendment to their Supply Agreement, originally established in 2014. This amendment is aimed at aligning their manufacturing and supply responsibilities better and includes a new capacity fee structure linked to FDA approval timelines for MannKind's product. The adjustments made are intended to facilitate smoother operations and clarify the financial commitments associated with product supply.
Read more →MNKDMANNKIND CORPORATION REPORTS 2023 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 3Q 2023 Total revenues of $51M; +56% vs. 3Q 2022 • 3Q YTD 2023 Total revenues of $140M; +
MannKind Corporation reported significant financial growth in its third quarter of 2023, with total revenues of $51 million, representing a 56% increase compared to the previous year. The company achieved a net income of $2 million and experienced remarkable growth in royalties from Tyvaso DPI, which rose by 225%. However, net revenue from V-Go decreased by 18%, highlighting some challenges within its product lines. The rise in R&D expenses signals ongoing investments in pipeline development, particularly in inhaled clofazimine and other projects.
Read more →MNKD▼ -7.1%on this newsshared move
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
MannKind Corporation has announced the successful completion of enrollment for its Phase 4 INHALE-3 clinical trial, which evaluates inhaled insulin in adults with type 1 diabetes. The trial aims to assess the efficacy of Afrezza in conjunction with basal insulin compared to standard care. Initial meal data is expected to be presented in 1Q 2024, followed by the primary endpoint analysis in 2Q 2024. The rapid enrollment showcases significant interest and commitment from the study investigators and participants.
Read more →MNKDMannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
MannKind Corporation will announce its 2023 third quarter financial results on November 7, 2023, at 5:00 PM ET. The conference call will feature CEO Michael Castagna and CFO Steven Binder discussing financial details and corporate updates. Stakeholders can access the call through the company's investor relations website. MannKind is dedicated to developing innovative treatments for unmet medical needs in endocrine and orphan lung diseases.
Read more →MNKD▲ +6.4%on this newsshared move
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
MannKind Corporation announced the issuance of a new patent for its inhaled clofazimine formulation, MNKD-101, aimed at treating nontuberculous mycobacterial (NTM) lung disease. The patent, which expires in June 2039, is seen as crucial for the protection of this lead pipeline asset. MNKD-101 has gained attention due to promising early data suggesting improved patient tolerance compared to existing treatments. Given the rising prevalence of NTM lung disease, this development may address a significant health concern affecting many patients in the U.S.
Read more →MNKDMANNKIND CORPORATION REPORTS 2023 SECOND QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 2Q 2023 Total revenues of $49M; +157% vs. 2Q 2022 • 2Q 2023 Tyvaso DPI royalties of $19M
MannKind Corporation reported strong financial results for the second quarter of 2023, with total revenues reaching $49 million, a 157% increase from the same period last year. Significant contributions came from Tyvaso DPI royalties and Afrezza sales, both showing substantial growth. The company reported positive income from operations and anticipates the Endocrine Business Unit will achieve profitability in 2024. Despite increased expenses in research and development, the overall outlook remains optimistic.
Read more →MNKDMannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
MannKind Corporation has announced that CEO Michael Castagna will participate in one-on-one meetings at the 2023 Wedbush PacGrow Healthcare Conference. The conference is scheduled for August 8, 2023, in New York City. MannKind specializes in developing inhaled therapeutic products aimed at treating endocrine and orphan lung diseases. The company's goal is to provide innovative solutions that improve the health and quality of life for patients with unmet medical needs.
Read more →MNKDMannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
MannKind Corporation is set to release its second quarter financial results on August 7, 2023, along with year-to-date results. The conference call will feature leadership from CEO Michael Castagna and CFO Steven Binder, discussing the company's performance and corporate updates. Interested parties can access the call live through the company's investor relations website. MannKind is focused on developing innovative therapies for serious medical needs, particularly in endocrine and orphan lung diseases.
Read more →MNKDMannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
MannKind Corporation has announced the launch of the INHALE-3 study aimed at improving mealtime glycemic control in adults with Type 1 Diabetes (T1D) through the use of inhaled insulin, Afrezza. This large, randomized controlled trial will compare the effectiveness of Afrezza with existing insulin delivery methods over a 17-week period. The study addresses a significant unmet need, as approximately 80% of adults with T1D struggle to achieve their glycemic targets. Conducted in collaboration with 20 clinical sites nationwide, the results aim to provide impactful insights into the management of diabetes.
Read more →MNKD▲ +15.8%on this news
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
MannKind Corporation will participate in the 2023 RBC Capital Markets Global Healthcare Conference, with CEO Michael Castagna leading a Fireside Chat on May 16, 2023. The event aims to showcase the company's focus on developing inhaled therapeutic products for endocrine and orphan lung diseases. Interested individuals can access a live webcast, which will also be available for replay for 14 days. This participation emphasizes MannKind's commitment to addressing serious medical needs through its innovative devices and therapies.
Read more →MNKD▲ +15.8%on this news
MANNKIND CORPORATION REPORTS 2023 FIRST QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 • 1Q 2023 Revenues associated wi
MannKind Corporation reported its financial results for the first quarter of 2023, highlighting a remarkable 239% surge in total revenues to $41 million compared to the same quarter in 2022. The strong demand for Tyvaso DPI significantly contributed to the revenues, reaching $23 million. Additionally, the company achieved a 72% reduction in its loss from operations, indicating improved financial health. However, the gross margin for its commercial products saw a decline due to the addition of lower-margin products, and research expenses also increased as they continue to develop their product pipeline.
Read more →MNKD▼ -6.1%on this news
MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
MannKind Corporation (Nasdaq: MNKD) will hold a conference call on May 9, 2023, to discuss its first quarter financial results. The call will feature CEO Michael Castagna and CFO Steven Binder. Interested parties can listen live via the company's investor relations website. MannKind specializes in developing products for serious medical conditions, including diabetes and pulmonary diseases.
Read more →MNKDLAUREN SABELLA JOINS MANNKIND AS EXECUTIVE VICE PRESIDENT
MannKind Corporation has announced the appointment of Lauren Sabella as Executive Vice President and Chief Operating Officer. Sabella will oversee critical operations in Danbury, focusing on expanding the company's endocrine business and upcoming pipeline launches in orphan lung diseases. With a robust background in various pharmaceutical roles, she is expected to enhance MannKind’s operational capabilities during a strategic phase for the company.
Read more →MNKDMannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
MannKind Corporation (Nasdaq: MNKD) announced that its CEO, Michael Castagna, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023. This participation highlights the company's ongoing commitment to developing inhaled therapeutic products for patients with endocrine and orphan lung diseases. The presentation will be accessible via their website and will have a replay available for 14 days post-event. MannKind focuses on addressing unmet medical needs through innovative technology and formulations.
Read more →MNKDMANNKIND CORPORATION REPORTS 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) 2022 Total Revenues of $100 million; +32% vs. 2021 2022 Royalties from Tyvaso DPI of $16 m
MannKind Corporation has reported a significant growth in revenues for 2022, reaching $100 million, a 32% increase compared to the previous year. The company highlighted a strong performance in its Afrezza product line, with net revenue increasing by 11%. However, collaboration revenues have decreased due to the completion of certain R&D services. The company is actively pursuing advancements in its product pipeline, including a Phase 3 trial for Afrezza in pediatrics and a Phase 2/3 study for inhaled clofazimine, set to start in late 2023.
Read more →MNKDMannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza With Basal Combination (ABC Study) at 16th Annual ATTD Conference
MannKind Corporation is set to present positive results from its Afrezza with Basal Combination study at the 16th Annual ATTD Conference. The data indicates that inhaled Technosphere Insulin (TI) lowers peak glucose levels significantly faster than traditional rapid-acting insulin. This pilot study suggests TI can help type 1 diabetes patients achieve better glucose control after meals. The company plans to conduct a larger study in the near future to explore these findings further.
Read more →MNKDMannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
MannKind Corporation (Nasdaq: MNKD) is scheduled to announce its financial results for the fourth quarter and the full year of 2022 on February 23, 2023. The company's CEO and CFO will present the results during a conference call at 5:00 PM Eastern Time. This event underscores MannKind's commitment to transparency and engagement with investors as it focuses on developing innovative therapeutic solutions for patients with serious health challenges. Interested parties can access the call live through MannKind's official website, with a replay available for a limited time.
Read more →MNKDMannkind Corporation to Participate in the SVB Securities Global Biopharma Conference
MannKind Corporation announced that its CEO, Michael Castagna, will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on February 15, 2023. The company specializes in developing and commercializing inhaled therapeutic products for patients with endocrine and orphan lung diseases. This event highlights MannKind's commitment to addressing serious medical needs and showcases their innovative delivery technologies. A webcast of the conference will be available for interested parties.
Read more →MNKD▲ +6.8%on this news
MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
MannKind Corporation announced its participation in the Lytham Partners Investor Select Conference, scheduled for January 31, 2023. CEO Michael Castagna and CFO Steven B. Binder will present the company's innovative developments in inhaled therapeutic products designed to address serious unmet medical needs. The presentation will be available for viewing on the company's website, and management will also engage in virtual one-on-one meetings with investors. MannKind's focus on rare diseases illustrates its commitment to enhancing patient care in the field of endocrine and lung diseases.
Read more →MNKDMannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
MannKind Corporation has announced its inhaled clofazimine suspension (MNKD-101) will progress to an adaptive Phase 2/3 study for treating nontuberculous mycobacterial (NTM) lung disease. This novel delivery method aims to reduce systemic toxicity and side effects associated with traditional oral treatments. A recent publication indicates the treatment shows promising tolerability and favorable drug retention in lung tissue. With rising cases of NTM lung disease globally, this development could provide a significant improvement in therapeutic options for affected patients.
Read more →MNKDMannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference
MannKind Corporation, a biopharmaceutical company specializing in innovative therapies for endocrine and orphan lung diseases, will have its CEO, Michael Castagna, present at the 2023 Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 12, 2023, in San Francisco, California. Interested parties can access the presentation via a live webcast, which will also be archived for later viewing. MannKind is focused on addressing unmet medical needs through advanced formulation and device engineering.
Read more →MNKD▲ +10.1%on this news
MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting
Technosphere® Insulin (TI) peaked 30 minutes faster and significantly reduced postprandial glucose excursions (PPGE) at 60 minutes compared to subcutaneous insulins The Afrezza with Basal Combination (ABC) Study demonstrated similar glucose control between the three treatment gr
Read more →MNKDMANNKIND CORPORATION REPORTS 2022 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 9:00 a.m. (ET) 3Q 2022 Total Revenues of $32.8 million; +48% vs. 3Q 2021 3Q 2022 Royalties from Tyvaso DPI of $6.2 milli
MANNKIND CORPORATION REPORTS 2022 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 9:00 a.m. (ET) DANBURY, Conn. and WESTLAKE VILLAGE, Calif. November 8, 2022 (Globe Newswire) - MannKind Corporation (Nasdaq: MNKD) today reported financial results for the third
Read more →MNKDMannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates
Read more →MNKDMannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today
Read more →MNKD▼ -5.3%on this news
Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
Study supports the dosing regimen that will be pursued in further clinical programs No serious adverse events or QT prolongation identified Planning underway to discuss results and the ongoing clinical program with the FDA DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 06,
Read more →MNKD▲ +9%on this newsshared move
MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today
Read more →MNKD▼ -6%on this news
MANNKIND CORPORATION REPORTS 2022 SECOND QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) Tyvaso DPI TM approved by the FDA in May representing the second FDA-approved product using the Technosp
MANNKIND CORPORATION REPORTS 2022 SECOND QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) DANBURY, Conn. and WESTLAKE VILLAGE, Calif. August 9, 2022 (Globe Newswire) - MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second
Read more →MNKD▲ +10.1%on this news· ran to +21% by day 3
MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 second quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates
Read more →MNKDMannKind Corporation to Participate in the BTIG Biotechnology Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today
Read more →MNKD▲ +11.4%on this news
Mannkind to Host Product Theater and Booth at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans, June 3-7
WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will showcase its mealtime insulin
Read more →MNKDMannKind’s Technosphere Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
Tyvaso DPI represents the second FDA-approved product utilizing MannKind’s Technosphere® inhalation technology First approval of a dry powder inhaled treatment for PAH and PH-ILD Manufacturing of Tyvaso DPI for United Therapeutics underway at MannKind’s Connecticut facility wit
Read more →MNKDMANNKIND'S TECHNOSPHERE INHALATION PLATFORM UTILIZED IN FDA-APPROVED TYVASO DPI Tyvaso DPI represents the second FDA-approved product utilizing MannKind's Technosphere inhalation technology First ap
MANNKIND'S TECHNOSPHERE INHALATION PLATFORM UTILIZED IN FDA-APPROVED TYVASO DPI DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 24, 2022 (Globe Newswire) - MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic
Read more →MNKD▲ +10%on this news· ran to +25% by day 3shared move
MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that
Read more →MNKD▲ +9.8%on this news· ran to +20% by day 3shared move
MannKind Corporation Announces Agreement to Acquire V-Go Insulin Delivery Device From Zealand Pharma
The once-daily insulin delivery device strengthens MannKind’s commitment to offering innovative mealtime diabetes solutions DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and
Read more →MNKD▼ -6.1%on this news
MannKind Corporation Participating at Upcoming Conferences
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that
Read more →MNKDMANNKIND CORPORATION REPORTS 2022 FIRST QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) 1Q 2022 Afrezza Net Revenue of $9.8 million; +21% vs. 1Q 2021 1Q 2022 Afrezza Gross Margin 77%; Gross Pro
MANNKIND CORPORATION REPORTS 2022 FIRST QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) DANBURY, Conn. and WESTLAKE VILLAGE, Calif. May 5, 2022 (Globe Newswire) - MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter en
Read more →MNKDMannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00
Read more →MNKDMannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30
Simplified 2x dose of Technosphere® Insulin (TI) produced a statistically significant improvement in PPGE between Dose 1 & 2 from 45-120 minutes Higher dose of TI resulted in a mean difference of 52 mg/dL in PPGE at 120 minutes, with no new safety concerns WESTLAKE VILLAGE, Cal
Read more →MNKDMannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference
DANBURY, Conn., March 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Office
Read more →MNKD▲ +5.2%on this news
MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit
DANBURY, Conn., March 22, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Scientific Offic
Read more →MNKDMannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference
DANBURY, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Office
Read more →MNKD▼ -20.5%on this news
MANNKIND CORPORATION REPORTS 2021 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) 2021 Total Revenues of $75.4 million; +16% vs. 2020 4Q 2021 Afrezza Net Revenue of $11.3 m
MANNKIND CORPORATION REPORTS 2021 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) DANBURY, Conn. and WESTLAKE VILLAGE, Calif. February 24, 2022 (Globe Newswire) - MannKind Corporation (Nasdaq: MNKD) today reported financial resul
Read more →MNKDMannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2021 fourth quarter and full year financial results, and its management will host a conference call to discuss the financial results and corporate u
Read more →MNKDMannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference
DANBURY, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer
Read more →MNKDMannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference
DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer
Read more →MNKDMannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases
MannKind purchased an additional convertible note issued by Thirona Bio Nonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022 MannKind’s CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKi
Read more →MNKDMannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference
WESTLAKE VILLAGE, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be partic
Read more →MNKDMannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced the closi
Read more →MNKDMANNKIND CORPORATION REPORTS 2021 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2021 Total Revenues of $22.2 million; +45% vs. 3Q 2020 3Q 2021 Afrezza Net Revenue of $9.8 million; +3
MANNKIND CORPORATION REPORTS 2021 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) WESTLAKE VILLAGE, Calif., November 9, 2021 (Globe Newswire) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter and nine month
Read more →MNKDMannKind Presents Data at 21st Annual Diabetes Technology Meeting
A Technosphere® Insulin (TI) dose – approximately double the estimated mealtime subcutaneously (SC) injection dose – reduced postprandial glucose excursions (PPGE) without any severe hypoglycemia in the first two hours Higher dose of TI resulted in approximately 50 mg/dL improve
Read more →MNKDMannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021
WESTLAKE VILLAGE, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on
Read more →MNKDMannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza in Pediatric Population
WESTLAKE VILLAGE, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today the enrollment of the
Read more →MNKDMannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 29, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today th
Read more →MNKDMannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference
WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be parti
Read more →MNKDMannkind Corporation Participating at Upcoming Conferences
WESTLAKE VILLAGE, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be parti
Read more →MNKDMannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
WESTLAKE VILLAGE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Execut
Read more →MNKDMannKind Corporation Reports 2021 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET 2Q 2021 Total Revenues of $23.3 million; +54% vs. 2Q 2020 2Q 2021 Afrezza Net Revenue of $10.0 million; +43%
MannKind Corporation Reports 2021 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET WESTLAKE VILLAGE, Calif., August 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the quarter and six months ended
Read more →MNKDMannKind Corporation to Hold 2021 Second Quarter Financial Results Conference Call on August 11, 2021
WESTLAKE VILLAGE, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on
Read more →MNKDMannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021
WESTLAKE VILLAGE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executi
Read more →MNKDMannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI™ With New Drug Application Acceptance From the FDA
Tyvaso DPI includes the second compound formulated with MannKind’s Technosphere® technology to be reviewed by the FDA FDA review expected to be complete in October 2021 Hiring expansion underway at MannKind’s manufacturing facility in Connecticut DANBURY, Conn., June 16, 2021
Read more →MNKDMannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases
MannKind will conduct formulation and preclinical studies of a new chemical entity owned by Thirona In addition, MannKind purchased a convertible note issued by Thirona WESTLAKE VILLAGE, Calif. and SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD)
Read more →MNKDMannKind Corporation at the Lytham Partners Summer 2021 Investor Conference
WESTLAKE VILLAGE, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executi
Read more →MNKDCERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. SIXTH A
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. SIXTH AMENDMENT TO SUPPLY AGREEMENT This sixth amendment ( Sixt
Read more →MNKDMannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly
Daly to drive bold “Tired of Pricks?” design for Ed Carpenter Racing at GMR Grand Prix on May 15 at Indianapolis Motor Speedway Indiana native to share personal journey and raise awareness about diabetes and innovative management options WESTLAKE VILLAGE, Calif. and INDIANAPO
Read more →MNKDMannKind Corporation Reports 2021 First Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET • 1Q 2021 Total Revenues of $17.4 million; +7% vs. 1Q 2020 • Received $230.0 million gross proc
MannKind Corporation Reports 2021 First Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET WESTLAKE VILLAGE, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the quarter ended March 31, 2021. "
Read more →MNKDMannKind Corporation to Participate in 2021 RBC Capital Markets Global Healthcare Conference
WESTLAKE VILLAGE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executiv
Read more →MNKDMannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021
WESTLAKE VILLAGE, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on W
Read more →MNKDExecution Version AMENDMENT NO. 7 TO CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 7 TO CREDIT AND SECURITY AGREEMENT (this Agreement ) is made as of this 22nd day of April, 2021, by and among MANNKIND CORPORATION , a
AMENDMENT NO. 7 TO CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 7 TO CREDIT AND SECURITY AGREEMENT (this Agreement ) is made as of this 22nd day of April, 2021, by and among MANNKIND CORPORATION, a Delaware corporation ( MannKind ), MANNKIND LLC, a Delaware limited liabilit
Read more →MNKDMannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche
Paid Off Mann Group Non-Convertible Note of $35.1 Million in Principal plus $4.4 Million in Accrued Interest Prepaid $10.0 Million Owed Under MidCap Credit Facility and Increased Borrowings Available Under Tranche 3 to $60.0 Million Reduced Annual Interest Expense on Remaining
Read more →MNKDMannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDA
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., April 19, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and United Therapeutics (Nasdaq: UTHR) reached a milestone today in the development of Tyvaso DPI™ as United Therapeutics submitted a new drug application (NDA) to
Read more →MNKDMannKind Announces Closing of Initial Purchasers’ Option to Purchase Additional Convertible Senior Notes
WESTLAKE VILLAGE, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that on March 15, 2021 it issued an additional $30.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the "notes") pursuant to the exerci
Read more →MNKDMannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors
WESTLAKE VILLAGE, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that it will participate in the 2022 Medicare Part D Senior Savings Model, which is intended to improve the affordability of insulin for Medicare beneficiaries by cap
Read more →MNKDMannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference
WESTLAKE VILLAGE, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Execut
Read more →MNKDExecution Version AMENDMENT NO. 6 TO CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 6 TO CREDIT AND SECURITY AGREEMENT (this Agreement ) is made as of this 1st day of March, 2021, by and among MANNKIND CORPORATION , a
AMENDMENT NO. 6 TO CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 6 TO CREDIT AND SECURITY AGREEMENT (this Agreement ) is made as of this 1st day of March, 2021, by and among MANNKIND CORPORATION, a Delaware corporation ( MannKind ), MANNKIND LLC, a Delaware limited liability
Read more →MNKDMannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering
WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the pricing of $200.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the "notes") in a private placement (the "offering") to qualified
Read more →MNKDMannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference
WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Execut
Read more →MNKDMannKind Corporation Announces Proposed Private Placement of Convertible Senior Notes
WESTLAKE VILLAGE, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2026 (the "notes") i
Read more →MNKDMannKind Corporation Reports 2020 Fourth Quarter and Full Year Financial Results Conference Call to Begin Today at 9:00 AM ET 4Q 2020 Afrezza Net Revenue of $10.1 million; +30% vs. 4Q 2019 o Sequential Quarter Growth +38
MannKind Corporation Reports 2020 Fourth Quarter and Full Year Financial Results Conference Call to Begin Today at 9:00 AM ET WESTLAKE VILLAGE, California February 25, 2021 (GLOBE NEWSWIRE) - MannKind Corporation (NASDAQ:MNKD) today reported financial results for the fourth qua
Read more →MNKDMannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference
WESTLAKE VILLAGE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executi
Read more →MNKDMannKind Corporation to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021
WESTLAKE VILLAGE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 fourth quarter and full year financial results and its management will host a conference call to discuss the financial results and corporate updates at 9:00 AM (Ea
Read more →MNKDMannKind Corporation to Participate in H.C. Wainwright Bioconnect 2021 Conference
WESTLAKE VILLAGE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executi
Read more →MNKDOMNIBUS JOINDER AND AMENDMENT NO. 5 TO CREDIT AND SECURITY AGREEMENT AND AMENDMENT NO. 1 TO PLEDGE AGREEMENT This OMNIBUS JOINDER AND AMENDMENT NO. 5 TO CREDIT AND SECURITY AGREEMENT AND AMENDMENT NO. 1 TO PLEDGE AGREEME
OMNIBUS JOINDER AND AMENDMENT NO. 5 TO CREDIT AND SECURITY AGREEMENT AND AMENDMENT NO. 1 TO PLEDGE AGREEMENT This OMNIBUS JOINDER AND AMENDMENT NO. 5 TO CREDIT AND SECURITY AGREEMENT AND AMENDMENT NO. 1 TO PLEDGE AGREEMENT (this Agreement ) is made as of this 29th day of Decemb
Read more →MNKDMannKind and Vertice to Co-Promote Thyquidity™ (levothyroxine sodium) Oral Solution
WESTLAKE VILLAGE, Calif. and NEW PROVIDENCE, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and Vertice Pharma today announced that they have entered into a co-promotion agreement for Thyquidity™ (levothyroxine sodium) oral solution through MannKind’s
Read more →MNKDMannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc. Lead investigational product (inhaled clofazimine) designated by the FDA as an orphan drug and qualified infectious disease product
MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc. Lead investigational product (inhaled clofazimine) designated by the FDA as an orphan drug and qualified infectious disease product WESTLAKE VILLAGE, Calif., December 7, 2020 (GLOBE NEWSWIRE) MannKind Corpo
Read more →MNKDExecution Version AMENDMENT NO. 3 CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 3 TO CREDIT AND SECURITY AGREEMENT (this Agreement ) is made as of this 30 th day of November, 2020, by and among MANNKIND CORPORATION ,
AMENDMENT NO. 3 CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 3 TO CREDIT AND SECURITY AGREEMENT (this Agreement ) is made as of this 30th day of November, 2020, by and among MANNKIND CORPORATION, a Delaware corporation ( MannKind ), as a Borrower, MANNKIND LLC, a Delaware li
Read more →MNKDMannKind and MidCap Amend Credit Facility
$10 million funded immediately $25 million available upon TreT FDA approval Interest-only period extended to September 2022 WESTLAKE VILLAGE, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that it and MidCap Financial Trust, as ag
Read more →MNKDMannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics
WESTLAKE VILLAGE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization o
Read more →MNKDMannKind Corporation Reports 2020 Third Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET • 3Q 2020 U.S. Afrezza Net Revenue of $7.3 million; +27% vs. 3Q 2019 • 3Q YTD 2020 U.S. Afrezza
MannKind Corporation Reports 2020 Third Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET WESTLAKE VILLAGE, Calif., November 4, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and nine months ende
Read more →MNKDMannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020
WESTLAKE VILLAGE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on
Read more →MNKDExecution Version AMENDMENT NO. 2 CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT (this Agreement ) is made as of this 21st day of August, 2020, by and among MANNKIND CORPORATION , a D
AMENDMENT NO. 2 CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT (this Agreement ) is made as of this 21st day of August, 2020, by and among MANNKIND CORPORATION, a Delaware corporation ( MannKind ), as a Borrower, MANNKIND LLC, a Delaware lim
Read more →MNKDMannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020
WESTLAKE VILLAGE, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executiv
Read more →MNKDMannKind Corporation Reports 2020 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET • 2Q 2020 Afrezza Net Revenue of $7.0 million; +15% vs. 2Q 2019 • 1H 2020 Afrezza Net Revenue
MannKind Corporation Reports 2020 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET WESTLAKE VILLAGE, Calif., August 5, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and six months ended
Read more →MNKDMannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020
WESTLAKE VILLAGE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on
Read more →MNKDMannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference
WESTLAKE VILLAGE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 1
Read more →MNKDMannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions
WESTLAKE VILLAGE, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza® (insulin human) Inhalation Powder was presented at the American Diabetes Association’s 80th Scientific Sessions, June 12-16, 2
Read more →MNKDMannKind Corporation Reports 2020 First Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET • 1Q 2020 Afrezza Net Revenue of $8.0 million; +58% vs. 1Q 2019 • 1Q 2020 Afrezza gross profit
MannKind Corporation Reports 2020 First Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET WESTLAKE VILLAGE, Calif., May 6, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended March 31, 2020. "W
Read more →MNKDMannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020
WESTLAKE VILLAGE, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on
Read more →MNKDNOTE Date 4/9/2020 Note Amount $4,872,860 Borrower MannKind Corporation Lender JPMorgan Chase Bank, N.A. 1. PROMISE TO PAY . Borrower promises to pay to the order of Lender the Note Amount, plus interest on the unpaid pr
Date 4/9/2020 Note Amount $4,872,860 Borrower MannKind Corporation Lender JPMorgan Chase Bank, N.A. Borrower promises to pay to the order of Lender the Note Amount, plus interest on the unpaid principal balance at the Note Rate, and all other amounts required by this "CARES Act
Read more →MNKDMannKind Receives Forgivable Loan under the Paycheck Protection Program
Investor call today at 4:30 pm ET to discuss operational update and cost-saving measures being implemented $4.9 million forgivable loan received Pay temporarily reduced by 20% for certain employees WESTLAKE VILLAGE, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporati
Read more →MNKDJennifer Grancio Appointed to MannKind Board of Directors
Jennifer Grancio Appointed to MannKind Board of Directors WESTLAKE VILLAGE, Calif., March 24, 2020 MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020. Ms. Grancio will also serve as a m
Read more →MNKDMannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic
WESTLAKE VILLAGE, Calif., March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is adjusting research and development resources that were reserved
Read more →MNKDMannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results Conference Call to Begin Today at 9:00 AM ET • 2019 Total Revenue of $63.0 million o 2019 Afrezza Net Revenue of $25.3 million; +46%
MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results Conference Call to Begin Today at 9:00 AM ET WESTLAKE VILLAGE, California February 25, 2020 (GLOBE NEWSWIRE) - MannKind Corporation (NASDAQ:MNKD) today reported financial results for the fourth qua
Read more →MNKDMannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference
WESTLAKE VILLAGE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced t
Read more →MNKDMannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)
WESTLAKE VILLAGE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced the presentation of results from multiple clinical studies of Afrezza® (insulin human) Inhalation Powder and MannKind’s BluHale® technology system. These data are being
Read more →MNKDMannKind Corporation to Hold 2019 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2020
WESTLAKE VILLAGE, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2019 fourth quarter and full year financial results and its management will host a conference call to discuss the financial results and corporate updates at 9:00 AM (Ea
Read more →MNKDExecution Version AMENDMENT NO. 1 CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 1 TO CREDIT AND SECURITY AGREEMENT (this Agreement ) is made as of this 18th day of December, 2019, by and among MANNKIND CORPORATION , a
AMENDMENT NO. 1 CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 1 TO CREDIT AND SECURITY AGREEMENT (this Agreement ) is made as of this 18th day of December, 2019, by and among MANNKIND CORPORATION, a Delaware corporation ( MannKind ), as a Borrower, MANNKIND LLC, a Delaware l
Read more →MNKDMannKind Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference
WESTLAKE VILLAGE, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced t
Read more →MNKDMannKind Appoints Tony Hooper to Its Board of Directors
MannKind Appoints Tony Hooper to Its Board of Directors WESTLAKE VILLAGE, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) MannKind Corporation (NASDAQ:MNKD) today announced that Anthony Hooper will join its Board of Directors, effective January 1, 2020. Mr. Hooper will also serve as a m
Read more →MNKDMannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results Conference Call to Begin Today at 9:00 AM ET • 3Q 2019 Total Revenues of $14.6 million; +227% vs. 3Q 2018 o 3Q 2019 Afrezza Net Revenue
MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results Conference Call to Begin Today at 9:00 AM ET WESTLAKE VILLAGE, California November 6, 2019 (GLOBE NEWSWIRE) - MannKind Corporation (NASDAQ:MNKD) today reported preliminary financial results for the qu
Read more →MNKDMannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics
WESTLAKE VILLAGE, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development an
Read more →MNKDMannKind Corporation to Hold 2019 Third Quarter Financial Results Conference Call on November 6, 2019
WESTLAKE VILLAGE, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2019 third quarter and year-to-date financial results and its management will host a conference call to discuss the financial results and corporate updates at 9:00 AM (
Read more →MNKDMannKind Corporation to Present at the 2019 Cantor Global Healthcare Conference
WESTLAKE VILLAGE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced
Read more →MNKDMannKind Presents Positive Afrezza Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD
WESTLAKE VILLAGE, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder was presented at the 55th Annual Meeting of the European Association for the Study of Diabetes
Read more →MNKDMannKind Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference
WESTLAKE VILLAGE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced t
Read more →MNKDMannKind Corporation Reports 2019 Second Quarter Financial Results and Recent Business Highlights Conference Call to Begin Today at 5:00 PM ET • 2Q 2019 Total Revenues of $15.0 million; +285% vs. 2Q 2018 o 2Q 2019
MannKind Corporation Reports 2019 Second Quarter Financial Results and Recent Business Highlights Conference Call to Begin Today at 5:00 PM ET WESTLAKE VILLAGE, California August 7, 2019 (GLOBE NEWSWIRE) - MannKind Corporation (NASDAQ:MNKD) today reported financial results for
Read more →MNKDCERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. Execution Version CRE
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. CREDIT AND SECURITY AGREEMENT dated as of August 6, 2019 MANNKIND LLC, each a
Read more →MNKDMannKind and One Drop Sign Collaboration Agreement to Integrate Bluetooth-Connected Inhaler with Dose Detection into the One Drop Platform
WESTLAKE VILLAGE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) and One Drop today announced that they have signed a collaborative agreement that is intended to integrate MannKind’s BluHale® accessory device into the One Drop platform. BluHale is
Read more →MNKDMannKind Corporation to Hold 2019 Second Quarter Financial Results Conference Call on August 7, 2019
WESTLAKE VILLAGE, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) will release its 2019 second quarter and year-to-date financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM
Read more →MNKDExecution Version EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this Agreement ) dated as of
This EXCHANGE AGREEMENT (this Agreement ) dated as of July 18, 2019, is by and among MannKind Corporation, a Delaware corporation (the Borrower ), MannKind LLC, a Delaware limited liability company ( Guarantor and together with the Borrower, collectively, the Obligors ), Deerfie
Read more →MNKDMannKind Repays Maturing Debt Obligation; Buys Back Certain Warrants
WESTLAKE VILLAGE, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced the repayment of outstanding debt by an aggregate amount of approximately $4.0 million and the repurchase of a warrant to purchase approximately 3.3 million shares of c
Read more →MNKDMannKind Partners with GoodRx to Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients
More than 65,000 patients pay over $200 per month for their mealtime insulin Commercially insured patients can pay as little as $15 per month for inhaled insulin Underinsured and uninsured patients can pay as little as $5 a day with MannKind direct purchase program WESTLAKE VI
Read more →MNKDMannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules
WESTLAKE VILLAGE, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced th
Read more →MNKDExecution Version ELEVENTH AMENDMENT TO FACILITY AGREEMENT This ELEVENTH AMENDMENT TO FACILITY AGREEMENT (this Amendment ) dated as of
ELEVENTH AMENDMENT TO FACILITY AGREEMENT This ELEVENTH AMENDMENT TO FACILITY AGREEMENT (this Amendment ) dated as of June 18, 2019, is by and among MannKind Corporation, a Delaware corporation (the Borrower ), MannKind LLC, a Delaware limited liability company (the Guarantor, a
Read more →MNKDMannKind to Present at the JMP Securities Life Sciences Conference
WESTLAKE VILLAGE, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced t
Read more →MNKDMannKind Presents Positive Afrezza Clinical Data from Three Studies at ADA 79th Scientific Sessions
WESTLAKE VILLAGE, Calif., June 09, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from three different studies of Afrezza® (insulin human) Inhalation Powder were released at the American Diabetes Association’s 79th Scientific Sessions, being
Read more →MNKDMannKind Announces Afrezza Distribution Agreement in Australia
WESTLAKE VILLAGE, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that it has entered into an exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd. for the commercializ
Read more →MNKDMannKind Corporation Reports 2019 First Quarter Financial Results Conference Call to Begin Today at 9:00 AM ET • 1Q 2019 Total Revenues of $17.4 million o 1Q 2019 Afrezza Net Revenue was $5.1 million; +49% vs. 1Q
MannKind Corporation Reports 2019 First Quarter Financial Results Conference Call to Begin Today at 9:00 AM ET WESTLAKE VILLAGE, CA, May 7, 2019 (GLOBE NEWSWIRE) - MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended March 31, 2019. "In the
Read more →MNKDMannKind Corporation to Hold 2019 First Quarter Financial Results Conference Call on May 7, 2019
WESTLAKE VILLAGE, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2019 first quarter financial results on Tuesday, May 7, 2019 and its management will host a conference call to discuss the financial results and other Company developm
Read more →MNKDMannKind Presents Scientific Data at 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE 2019)
WESTLAKE VILLAGE, Calif., April 25, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced additional data supporting the distinct clinical profile of Afrezza will be presented in an e-poster presentation on Thursday, April 25, 2019 at the 28th Annual Scienti
Read more →MNKDMannKind to Present at the H.C. Wainwright Global Life Sciences Conference
WESTLAKE VILLAGE, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced
Read more →MNKDMannKind Receives $12.5 Million Milestone Payment from United Therapeutics
WESTLAKE VILLAGE, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and
Read more →MNKDMannKind to Sponsor Andretti Autosport Type 1 Diabetes Driver, Conor Daly
WESTLAKE VILLAGE, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) announced today it is sponsoring Conor Daly as he makes his debut with the Andretti Autosport team at the 103rd Running of the Indianapolis 500 on May 26, 2019. MannKind is an associat
Read more →MNKDMannKind Corporation Fourth Quarter and Year-End 2018 Earnings Call Conference Call to Begin Today at 9:00 AM ET • 4Q 2018 Total Revenues were $16.0 million; 254% growth vs. 4Q 2017 o 4Q 2018 Afrezza Net Revenue w
MannKind Corporation Fourth Quarter and Year-End 2018 Earnings Call Conference Call to Begin Today at 9:00 AM ET WESTLAKE VILLAGE, CA, February 26, 2019 (GLOBE NEWSWIRE) - MannKind Corporation (NASDAQ:MNKD) today reported financial results for the fourth quarter and full year e
Read more →MNKDMannKind Presents New Scientific Data at 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)
WESTLAKE VILLAGE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced additional positive Afrezza clinical data to be presented in an oral presentation on Thursday, February 21, 2019 and a poster on Wednesday, February 20, 2019 at the 12th
Read more →MNKDMannKind Corporation to Hold 2018 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2019
WESTLAKE VILLAGE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2018 fourth quarter and full year financial results on Tuesday, February 26, 2019 and its management will host a conference call to discuss the financial results and ot
Read more →MNKDMannKind Announces Direct Purchase Insulin Program Providing Afrezza for as low as $4 a Day
WESTLAKE VILLAGE, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announ
Read more →MNKDMannKind Corporation to Hold Investor Conference Call
WESTLAKE VILLAGE, Calif., Dec. 27, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) will host a conference call on Friday, January 4, 2019 to discuss Company developments at 9:00 AM (Eastern Time). Presenting from the Company will be its Chief Executive Officer, Mich
Read more →MNKDMannKind Announces Pricing of $40 Million Public Offering
WESTLAKE VILLAGE, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) (MannKind) today announced the pricing of an underwritten public offering of 26,666,667 shares of its common stock and warrants to purchase up to an aggregate of 26,666,667 shares of i
Read more →MNKDMannKind Announces Commencement of Public Offering Westlake Village, CA
MannKind Announces Commencement of Public Offering Westlake Village, CA, December 19, 2018 MannKind Corporation (Nasdaq: MNKD) (MannKind) today announced that it has commenced an underwritten public offering to issue and sell shares of its common stock and warrants to purchase
Read more →MNKDMannKind Appoints Christine Mundkur to its Board of Directors
MannKind Appoints Christine Mundkur to its Board of Directors WESTLAKE VILLAGE, Calif., Nov. 27, 2018 MannKind Corporation (Nasdaq: MNKD) today announced that Christine Mundkur has joined its Board of Directors, effective November 27, 2018. Ms. Mundkur will also serve as a memb
Read more →MNKDMannKind Corporation Reports 2018 Third Quarter Financial Results Conference Call to Begin Today at 9:00 AM ET • Executed license and collaboration agreement with United Therapeutics for up to $95 million in upfro
MannKind Corporation Reports 2018 Third Quarter Financial Results Conference Call to Begin Today at 9:00 AM ET WESTLAKE VILLAGE, CA, November 1, 2018 (GLOBE NEWSWIRE) - MannKind Corporation (NASDAQ:MNKD) today reported financial results for the third quarter ended September 30,
Read more →MNKDMannKind Corporation to Hold 2018 Third Quarter Financial Results Conference Call on November 1, 2018
WESTLAKE VILLAGE, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host a conference call to discuss the 2018 third quarter and year-to-date financial results and other corporate developments at 9:00 AM (Eastern Time) on Thursday, November 1, 201
Read more →MNKDUNITED THERAPEUTICS AND MANNKIND ANNOUNCE CLOSING OF LICENSE AND COLLABORATION AGREEMENT Research Triangle Park, North Carolina and Westlake Village, California
UNITED THERAPEUTICS AND MANNKIND ANNOUNCE CLOSING OF LICENSE AND COLLABORATION AGREEMENT Research Triangle Park, North Carolina and Westlake Village, California, October 16, 2018 United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today annou
Read more →MNKDMannKind Presents Positive Afrezza STAT Study Clinical Data at 54th Annual Meeting of the European Association for the Study of Diabetes
Poster 813; PS 068 Improved post-prandial blood glucose excursions with Technosphere inhaled insulin compared to aspart in adult patients with type 1 diabetes: STAT study intention to treat analysis Poster 677; PS 051 Improved time-in-range on continuous glucose monitor with Te
Read more →MNKDMannKind Presents New Scientific Data at 54th Annual Meeting of the European Association for the Study of Diabetes
Presentation 55 Total and severe hypoglycemia is reduced with use of inhaled Technosphere® Insulin (TI) relative to insulin aspart in type 1 diabetes Poster 1046; PS 097 Diabetes duration, BMI, and HbA1c have greater effects on Pulmonary Function (PF) than inhaled Technosphere
Read more →MNKDTENTH AMENDMENT TO FACILITY AGREEMENT This TENTH AMENDMENT TO FACILITY AGREEMENT (this Amendment ) dated as of
TENTH AMENDMENT TO FACILITY AGREEMENT This TENTH AMENDMENT TO FACILITY AGREEMENT (this Amendment ) dated as of September 26, 2018, is by and among MannKind Corporation, a Delaware corporation (the Borrower ), MannKind LLC, a Delaware limited liability company (the Guarantor, an
Read more →MNKDMannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
WESTLAKE VILLAGE, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) announced today that Cohort 2 of the Afrezza® safety and pharmacokinetics study in pediatric patients is now open for enrollment. The first group of individuals participating in the o
Read more →MNKDNINTH AMENDMENT TO FACILITY AGREEMENT This NINTH AMENDMENT TO FACILITY AGREEMENT (this Amendment ) dated as of
NINTH AMENDMENT TO FACILITY AGREEMENT This NINTH AMENDMENT TO FACILITY AGREEMENT (this Amendment ) dated as of September 5, 2018, is by and among MannKind Corporation, a Delaware corporation (the Borrower ), MannKind LLC, a Delaware limited liability company (the Guarantor, and
Read more →MNKDMannKind Corporation to Present at Upcoming Conferences
WESTLAKE VILLAGE, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced t
Read more →MNKDMannKind Corporation Reports 2018 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET • 2Q 2018 Afrezza Net Revenue was $3.8 million; 142% growth versus. 2Q 2017 • 2Q 2018 Afrezza
MannKind Corporation Reports 2018 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET WESTLAKE VILLAGE, CA, August 2, 2018 (GLOBE NEWSWIRE) - MannKind Corporation (NASDAQ:MNKD) today reported financial results for the second quarter ended June 30, 2018
Read more →MNKDMannKind and Tanner Pharma Group Enter into an ex-U.S. Distribution Agreement for Afrezza
WESTLAKE VILLAGE, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announ
Read more →MNKDMannKind Corporation to Hold 2018 Second Quarter Financial Results Conference Call on August 2, 2018
WESTLAKE VILLAGE, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host a conference call to discuss the 2018 second quarter and year-to-date financial results and other corporate developments at 5:00 PM (Eastern Time) on Thursday, August 2, 2018
Read more →MNKDEXECUTION VERSION EXCHANGE AND EIGHTH AMENDMENT TO FACILITY AGREEMENT This EXCHANGE AND EIGHTH AMENDMENT TO FACILITY AGREEMENT (this Agreement ) dated as of
EIGHTH AMENDMENT TO FACILITY AGREEMENT This EXCHANGE AND EIGHTH AMENDMENT TO FACILITY AGREEMENT (this Agreement ) dated as of July 12, 2018, is by and among MannKind Corporation, a Delaware corporation (the Borrower ), MannKind LLC, a Delaware limited liability company (the Gua
Read more →MNKDMannKind Set to Join Russell 3000 Index
WESTLAKE VILLAGE, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announ
Read more →MNKDMannKind Presents Positive Afrezza Clinical Data from STAT and AFFINITY Studies at ADA 78th Scientific Sessions
Poster 1017-P: Afrezza provides improved Time-in-Range on Continuous Glucose Monitoring compared to insulin aspart Poster 102-LB: Hypoglycemia is reduced with use of Afrezza compared to insulin aspart WESTLAKE VILLAGE, Calif., June 23, 2018 (GLOBE NEWSWIRE) -- MannKind Corpo
Read more →MNKDMannKind to Host Institutional Investor and Analyst Meeting
Renowned Endocrinology Expert Presenting Current Trends in Treatment and Management of Diabetes MannKind’s Chief Medical Officer Presenting New Afrezza® Data Released at American Diabetes Association’s 78th Scientific Sessions WESTLAKE VILLAGE, Calif., June 20, 2018 (GLOBE NEWS
Read more →MNKDExecution Version EXCHANGE AND SEVENTH AMENDMENT TO FACILITY AGREEMENT This EXCHANGE AND SEVENTH AMENDMENT TO FACILITY AGREEMENT (this Agreement ) dated as of
SEVENTH AMENDMENT TO FACILITY AGREEMENT This EXCHANGE AND SEVENTH AMENDMENT TO FACILITY AGREEMENT (this Agreement ) dated as of June 8, 2018, is by and among MannKind Corporation, a Delaware corporation (the Borrower ), MannKind LLC, a Delaware limited liability company (the Gu
Read more →MNKDMannKind Successfully Completes Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension Advancing Development to Next Phase
Study achieved primary endpoint of safety and tolerability Progressive dosing of Treprostinil Technosphere (TreT) significantly exceeded the corresponding peak plasma and exposure levels of the maximum recommended dose of Tyvaso® Inhalation Solution Achieved a maximum tolerated
Read more →MNKDMannKind Establishes Market Price Stock Purchase Plan
WESTLAKE VILLAGE, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) has established a stock purchase plan that provides MannKind’s directors and executive officers with a way to purchase shares of common stock directly from the Company at the prevailing
Read more →MNKDEXCHANGE AGREEMENT [ ] (the Undersigned ), for itself and on behalf of the beneficial owner listed on Exhibit A hereto (the Account and the Holder ) for whom the Undersigned holds contractual and investment authority, en
[ ] (the Undersigned ), for itself and on behalf of the beneficial owner listed on Exhibit A hereto (the Account and the Holder ) for whom the Undersigned holds contractual and investment authority, enters into this Exchange Agreement (this Agreement ) with MannKind Corporation
Read more →MNKDMannKind and Cipla Enter an Exclusive Marketing and Distribution Agreement for Afrezza in India
WESTLAKE VILLAGE, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announc
Read more →MNKDMannKind Corporation Reports 2018 First Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET • Q1 2018 Afrezza Net Revenue was $3.4 million; +184% vs. Q1 2017 (+234% under the 2017 revenue recogn
MannKind Corporation Reports 2018 First Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET WESTLAKE VILLAGE, CA, May 9, 2018 (GLOBE NEWSWIRE) - MannKind Corporation (NASDAQ:MNKD) today reported financial results for the first quarter ended March 31, 2018. "
Read more →MNKDMannKind Corporation to Hold 2018 First Quarter Financial Results Conference Call on May 9, 2018
WESTLAKE VILLAGE, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2018 first quarter financial results on Wednesday, May 9, 2018 and its management will host a conference call to discuss the financial results and other Company developm
Read more →MNKDMannKind Announces Completion of Previously Announced $28.0 Million Registered Direct Offering
WESTLAKE VILLAGE, Calif., April 09, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced the completion of its previously announced registered direct offering of 14,000,000 shares of common stock and warrants to purchase up to an aggregate of 14,000,000 sha
Read more →MNKDMannKind Announces $28.0 Million Registered Direct Offering
WESTLAKE VILLAGE, Calif., April 06, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced the pricing of a registered direct offering of 14,000,000 shares of common stock and warrants to purchase up to an aggregate of 14,000,000 shares of common stock to sel
Read more →MNKDFORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of
FORM OF SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of April 5, 2018, between MannKind Corporation, a Delaware corporation (the Company ), and each purchaser identified on the signature pages hereto (each, including its success
Read more →MNKDMannKind Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference
WESTLAKE VILLAGE, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced it wil
Read more →MNKDMannKind Corporation to Present at Oppenheimer 28th Annual Healthcare Conference
WESTLAKE VILLAGE, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that i
Read more →MNKDMannKind Announces STAT Study Results Accepted for Presentation at American Diabetes Association’s 78th Scientific Sessions
WESTLAKE VILLAGE, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that r
Read more →MNKDMannKind Restructures $79.7 Million Debt Obligation to the Mann Group and Reduces Principal Owed to Deerfield by $6.3 Million
WESTLAKE VILLAGE, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced the restructuring of certain of its outstanding debt obligations, reducing outstanding principal by an aggregate of $14.5 million along with the corresponding interest
Read more →MNKDExecution Version THE SECURITY REPRESENTED BY THIS CERTIFICATE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS SECURITY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR APPLICABLE STATE SECURITIES LAWS
THE SECURITY REPRESENTED BY THIS CERTIFICATE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS SECURITY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS SECURIT
Read more →MNKDMannKind Opens Enrollment of Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension
WESTLAKE VILLAGE, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that
Read more →MNKDMannKind Corporation Reports 2017 Fourth Quarter and Full Year Financial Results Conference Call to Begin Today at 5:00 PM ET • Q4 and 2H 2017 Afrezza net revenue were $4.5 million (+238%) and $6.4 million (+240%)
MannKind Corporation Reports 2017 Fourth Quarter and Full Year Financial Results Conference Call to Begin Today at 5:00 PM ET WESTLAKE VILLAGE, CA, February 27, 2018 (GLOBE NEWSWIRE) - MannKind Corporation (NASDAQ:MNKD) today reported financial results for the fourth quarter an
Read more →MNKDMannKind Corporation to Hold 2017 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2018
WESTLAKE VILLAGE, Calif., Feb. 23, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2017 fourth quarter and full year financial results on Tuesday, February 27, 2018 and its management will host a conference call to discuss the financial results and ot
Read more →MNKDMannKind Corporation to Present at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference
WESTLAKE VILLAGE, Calif., Jan. 16, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that i
Read more →MNKDExecution Version FIFTH AMENDMENT TO FACILITY AGREEMENT This FIFTH AMENDMENT TO FACILITY AGREEMENT (this Amendment ) dated as of
AMENDMENT TO FACILITY AGREEMENT This FIFTH AMENDMENT TO FACILITY AGREEMENT (this Amendment ) dated as of January 15, 2018, is by and among MannKind Corporation, a Delaware corporation (the Borrower ), MannKind LLC, a Delaware limited liability company ( Guarantor , and together
Read more →MNKDMannKind Corporation Reports 2017 Third Quarter Financial Results Conference Call to Begin Today at 5:00
MannKind Corporation Reports 2017 Third Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET WESTLAKE VILLAGE, CA, Nov. 7, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today reported financial results for the third quarter and the nine months e
Read more →MNKDMannKind Corporation to Hold 2017 Third Quarter Financial Results Conference Call on November 7, 2017
WESTLAKE VILLAGE, Calif., Oct. 27, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) will release its 2017 third quarter financial results on Tuesday, November 7, 2017 and its management will host a conference call to discuss the third quarter financial resu
Read more →MNKDMannKind and BIOMM Submit Registration Dossier to Brazilian Health Regulatory Agency (ANVISA)
WESTLAKE VILLAGE, Calif. and BELO HORIZONTE, Brazil, Oct. 23, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) and BIOMM SA (B3:BIOM3) announced the submission of a registration dossier to ANVISA, seeking the approval of Afrezza® (insulin human) inhalation
Read more →MNKDExecution Version FOURTH AMENDMENT TO FACILITY AGREEMENT This FOURTH AMENDMENT TO FACILITY AGREEMENT (this Agreement ) dated as of
FOURTH AMENDMENT TO FACILITY AGREEMENT This FOURTH AMENDMENT TO FACILITY AGREEMENT (this Agreement ) dated as of October 23, 2017, is by and among MannKind Corporation, a Delaware corporation (the Borrower ), MannKind LLC, a Delaware limited liability company ( Guarantor , and
Read more →MNKDMannKind Restructures Near-Term Debt Obligations
New 5.75% Convertible Senior Subordinated Exchange Notes due 2021 and Common Stock to be Issued in Exchange for Existing Convertible Senior Subordinated Exchange Notes due 2018 Fourth Amendment to Facility Agreement with Deerfield and Amendment and Restatement of Deerfield Notes
Read more →MNKDMannKind Donates Afrezza to Support People with Diabetes Impacted by Hurricane Maria in Puerto Rico
WESTLAKE VILLAGE, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced the company’s support for Hurricane Maria victims in Puerto Rico with a donation of Afrezza® (insulin human) inhalation power. The donation will be delivered via A
Read more →MNKDMannKind Announces $61 Million Registered Direct Offering of Common Stock
MannKind Announces $61 Million Registered Direct Offering of Common Stock WESTLAKE VILLAGE, Calif., Oct. 10, 2017 (GLOBE NEWSWIRE) MannKind Corporation (NASDAQ:MNKD) and (TASE:MNKD) today announced that it entered into definitive agreements with certain institutional investors
Read more →MNKDExchange Agreement [ ] (the Investor ) enters into this Exchange Agreement (this Agreement ) with MannKind Corporation (the Company ) on
Investor ) enters into this Exchange Agreement (this Agreement ) with MannKind Corporation (the Company ) on September 29, 2017 whereby the Investor will exchange (the Exchange ) all of the Company s Series A Common Stock Purchase Warrants and Series B Common Stock Purchase Warr
Read more →MNKDMannKind Responds to Hurricane Harvey Devastation with Afrezza Donation
WESTLAKE VILLAGE, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today the company’s support for Hurricane Harvey victims with a donation of Afrezza® (insulin human) Inhalation Powder. The donation will be shipped this week to
Read more →MNKDMannKind Corporation Relocates Headquarters to Westlake Village
WESTLAKE VILLAGE, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today the company has fully relocated its corporate headquarters to a 12,596-square-foot location in the Westlake Landmark office park in Westlake Village, Califo
Read more →MNKDMannKind and One Drop Partner to Launch the A-ONE Clinical Trial
VALENCIA, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) and One Drop today announced the first step of their collaboration with the launch of the A-ONE study, a randomized controlled trial investigating the use of Afrezza® inhaled insuli
Read more →MNKDMannKind Corporation Reports 2017 Second Quarter Financial Results
VALENCIA, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today reported financial results for the second quarter and the six months ended June 30, 2017. Key results include: Completed commercial expansion Afrezza net revenue and gross
Read more →MNKDMannKind Corporation to Hold 2017 Second Quarter Financial Results Conference Call on August 7, 2017
VALENCIA, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) will release its 2017 second quarter financial results on Monday, August 7, 2017 and its management will host a conference call to discuss the second quarter financial results and o
Read more →MNKDOne Casper Street Danbury, CT 06810 Main: 203-798-8000 Fax: 203-798-7740 www.mannkindcorp.com
Mr. Steven B. Binder Congratulations! The MannKind team has been very impressed with your background and credentials, and we are genuinely pleased to offer you full-time employment with MannKind Corporation, in the exempt position Chief Financial Officer located in California.
Read more →MNKDMannKind Draws Remaining Funds under Mann Group Loan Arrangement
VALENCIA, Calif., June 29, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) and (TASE:MNKD), announced today that it has delivered a funding request notification to the Mann Group LLC pursuant to the terms of the Mann Group Loan Arrangement (the “Loan Arrangement”) to
Read more →MNKDMannKind Renegotiates Near-Term Maturities with Deerfield
VALENCIA, Calif., June 29, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) and affiliates of Deerfield Management Company L.P. (“Deerfield”) have entered into an exchange and third amendment to their facility agreement (the “Facility Agreement”), pursuant
Read more →MNKDAGREEMENT THIS AGREEMENT (this Agreement ) is entered into as of
(this Agreement ) is entered into as of June 27, 2017, effective as of June 30, 2017 (the Effective Date ), by and between MANNKIND CORPORATION, a Delaware corporation (the Borrower ) and THE MANN GROUP LLC ( Lender and together with the Borrower, the Parties ). WHEREAS, the Bo
Read more →MNKDMannKind Engages Locust Walk to Explore Strategic Options for MannKind’s Non-insulin Technosphere-based Pipeline Candidates
VALENCIA, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD), focused on the discovery, development and commercialization of therapeutic products, announces its decision to explore strategic and financial alternatives for MannKind’s novel Tec
Read more →MNKDMannKind and Biomm Enter Into Distribution Agreement for Afrezza in Brazil
VALENCIA, Calif. and BELO HORIZONTE, Brazil, May 31, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) and BIOMM SA (BVMF:BIOM3) today announced that they have entered into a supply and distribution agreement for the commercialization of Afrezza® (insulin hu
Read more →MNKDMannKind Provides Update on Senior Management
VALENCIA, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) announced today that its Board of Directors appointed Michael Castagna, Pharm.D., as Chief Executive Officer effective May 25, 2017. Dr. Castagna replaced Matthew Pfeffer, who served
Read more →MNKDMannKind Corporation Reports 2017 First Quarter Financial Results
VALENCIA, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today reported financial results for the first quarter ended March 31, 2017. Key results include: Total revenue for the quarter of $3.0 million Deferred revenue of $1.8 million as
Read more →MNKDMannKind and One Drop to collaborate on delivering better health outcomes for people with diabetes
VALENCIA, Calif. and NEW YORK, May 04, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) TASE:MNKD) and One Drop today announced that they have signed a memorandum of understanding to enter into a collaborative agreement that would extend One Drop’s subscription service
Read more →MNKDMannKind Corporation to Hold 2017 First Quarter Financial Results Conference Call on May 10, 2017
VALENCIA, Calif., April 28, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) will release its 2017 first quarter financial results on Wednesday, May 10, 2017 and its management will host a conference call to discuss the first quarter financial results and o
Read more →MNKDEXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this Agreement ) dated as of
EXCHANGE AGREEMENT (this Agreement ) dated as of April 18, 2017, is by and among MannKind Corporation, a Delaware corporation (the Borrower ), MannKind LLC, a Delaware limited liability company ( Guarantor ), Deerfield Private Design Fund II, L.P. ( DPDF ) and Deerfield Private
Read more →MNKDMannKind Corporation Change of Control Agreement This Change of Control Agreement (this Agreement ), dated and effective as of
MannKind Corporation Change of Control Agreement This Change of Control Agreement (this Agreement ), dated and effective as of April 6, 2017 (the Effective Date ), is between MannKind Corporation, a Delaware corporation (together with its affiliates, the Company ), and [ ] WH
Read more →MNKDMannKind Corporation Reports 2016 Fourth Quarter and Full Year Financial Results
Conference Call to Begin Today at 5:00 PM ET VALENCIA, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2016. Key results include: Total revenue for
Read more →MNKD: Rose Alinaya SVP, Finance 661-775-5300 ralinaya@mannkindcorp.com MannKind Corporation Reports 2016 Fourth Quarter and Full Year Financial Results Conference Call to Begin Today at 5:00
ralinaya@mannkindcorp.com MannKind Corporation Reports 2016 Fourth Quarter and Full Year Financial Results Conference Call to Begin Today at 5:00 PM ET VALENCIA, Calif., March 16, 2017 (GLOBE NEWSWIRE) MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today reported financial res
Read more →MNKDMannKind Corporation and Charles Mattocks Announce “REVERSED”-America’s First Docu-Series Tackling Diabetes
VALENCIA, Calif. and TAMPA, Fla., March 08, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation and Bella & Elle Media LLC announce MannKind’s sponsorship of “Reversed,” a production series aimed at educating the show’s participants and viewing audience about the effects of poorly mana
Read more →MNKDMannKind Corporation Announces Upcoming Events
- 29th Annual ROTH Conference on March 13, 2017 - - 2016 Fourth Quarter and Full Year Financial Results Conference Call on March 16, 2017 - VALENCIA, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) announced two upcoming events: Presen
Read more →MNKDMannKind Receives $16.7 Million From Sale of Valencia Property
VALENCIA, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today confirmed that it received $16.7 million on February 17, 2017, upon closing the sale of real estate owned by the Company in Valencia, California, net of closing costs. About
Read more →MNKDMannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza Growth
VALENCIA, Calif., Feb. 01, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD), a fully integrated biopharmaceutical company focusing on the discovery and development of therapeutic products for patients with diseases such as diabetes, announced today the laun
Read more →MNKDMannKind Corporation to Hold Investor Conference Call on February 1, 2017
VALENCIA, Calif., Jan. 27, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host a conference call to discuss Company developments at 5:00 PM (Eastern Time) on February 1, 2017. Presenting from the Company will be its Chief Executive Officer, Matthew
Read more →MNKDMannKind Receives $30.6 Million From Sanofi
VALENCIA, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today confirmed that it received $30.6 million from Sanofi on January 6, 2017, representing the balance of the accelerated insulin “put” option previously exercised by MannKind. Thi
Read more →MNKDAGREEMENT OF PURCHASE AND SALE AND JOINT ESCROW INSTRUCTIONS THIS AGREEMENT OF PURCHASE AND SALE AND JOINT ESCROW INSTRUCTIONS ( Agreement ) is made and entered into as of
AGREEMENT OF PURCHASE AND SALE AND JOINT ESCROW INSTRUCTIONS THIS AGREEMENT OF PURCHASE AND SALE AND JOINT ESCROW INSTRUCTIONS ( Agreement ) is made and entered into as of January 6, 2017 ( Execution Date ), by and between MANNKIND CORPORATION, a Delaware corporation ( Seller
Read more →MNKDMannKind Corporation to Present at the J.P. Morgan 2017 Healthcare Conference
VALENCIA, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD), focused on the discovery and development of therapeutic products for diabetes, will present today at the 35th Annual J.P. Morgan Healthcare Conference at 10:00 AM (PST) at the West
Read more →MNKDMannKind Announces Key Addition to Its Executive Management Ranks
VALENCIA, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced that Stuart A. Tross, Ph.D., has joined the company as its Chief People Officer, with responsibilities for Human Resources, Information Technology and West Coast Fac
Read more →MNKDMannKind Receives $1 Million Milestone From RLS
VALENCIA, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today confirmed that following the completion of initial formulation studies it received a $1 million milestone payment from Receptor Life Sciences, Inc. (RLS) on Friday, December 3
Read more →MNKDMannKind and Sanofi Reach Agreement on AFREZZA
VALENCIA, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced that MannKind and Sanofi have entered into an agreement with the following terms: The promissory note and security agreement between MannKind and Aventisub LLC, a S
Read more →MNKDMannKind Corporation Reports 2016 Third Quarter Financial Results - Conference Call to Begin Today at 5:00 PM ET
MannKind Corporation Reports 2016 Third Quarter Financial Results - Conference Call to Begin Today at 5:00 PM ET - VALENCIA, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today reported financial results for the three and nine months end
Read more →MNKDMannKind Corporation to Hold 2016 Third Quarter Financial Results Conference Call on November 9, 2016
VALENCIA, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) will release its 2016 third quarter financial results on Wednesday, November 9, 2016 and its management will host a conference call and presentation webcast to discuss the third qua
Read more →MNKDMannKind Corporation to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
VALENCIA, Calif., Sept. 02, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today that the Company will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 11:40 AM (ET) at the Lotte New York
Read more →MNKDMannKind Corporation Reports 2016 Second Quarter Financial Results Conference Call to Begin Today at 5:00
MannKind Corporation Reports 2016 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET Calif., Aug. 08, 2016 MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today reported financial results for the second quarter and the six months ended June 30, 2016.
Read more →MNKDMannKind Corporation to Hold 2016 Second Quarter Financial Results Conference Call on August 8, 2016
VALENCIA, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) will release its 2016 second quarter financial results on Monday, August 8, 2016 and its management will host a conference call to discuss the second quarter financial results and o
Read more →MNKDMannkind Assumes Responsibility for Distribution of Afrezza and Launches Patient Reimbursement and Adherence Support Programs
VALENCIA, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced it is now distributing MannKind-branded Afrezza® (insulin human) Inhalation Powder directly to major wholesalers and that Afrezza is available by prescription from retail
Read more →MNKDMannKind Corporation to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
VALENCIA, Calif., July 08, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today that the Company will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on Tuesday, July 12, 2016 at 3:30 PM (ET) at the Le Parker Meridien in New York
Read more →MNKDMannKind Announces Late-Breaking Data Reinforcing Faster Onset and Shorter Duration of Action Compared to Mealtime Insulins
Data presented at ADA show Afrezza has a 25-to 35-minute faster onset of action than Lispro, with a duration that is up to two hours shorter MannKind Corporation reaffirms commitment to Afrezza, the only inhaled insulin available in the U.S., in advance of product relaunch in Ju
Read more →MNKDMannKind Announces Collaboration with JDRF
VALENCIA, Calif., June 10, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today that it has entered into a collaboration agreement with JDRF (formerly known as Juvenile Diabetes Research Foundation), the leading global organization funding type
Read more →MNKDSECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of May 9, 2016, between MannKind Corporation, a Delaware corporation (the Company ), and each purchaser identified on the signature pages hereto (each, including its successors and as
Read more →MNKDMannKind Announces Pricing of Registered Direct Public Offering of Common Stock and Warrants
VALENCIA, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced the pricing of a registered direct public offering of up to 48,543,692 shares of common stock and warrants to purchase up to an aggregate of 48,543,692 shares of comm
Read more →MNKDMannKind Corporation Reports 2016 First Quarter Financial Results
VALENCIA, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today reported financial results for the first quarter ended March 31, 2016. For the first quarter of 2016, total operating expenses were $20.0 million as compared to $21.7 million
Read more →MNKDMannKind Corporation to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
VALENCIA, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today that the Company will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Thursday, May 12, 2016 at 8:00 AM (PDT) at the Encore at Wynn Hotel
Read more →MNKDMannKind Corporation to Hold 2016 First Quarter Financial Results Conference Call on May 9, 2016
VALENCIA, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) will release its 2016 first quarter financial results on Monday, May 9, 2016 and its management will host a conference call to discuss the first quarter financial results and other C
Read more →MNKDMANNKIND CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement
MANNKIND CORPORATION (par value $0.01 per At Market Issuance Sales Agreement FBR Capital Markets & Co. 1300 North 17th Street North Arlington, Virginia 22209 Ladies and Gentlemen: MannKind Corporation, a Delaware corporation (the Company ), confirms its agreement (this Ag
Read more →MNKDMannKind Expands Commercial Capabilities With Two New Hires
VALENCIA, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced two senior appointments to its commercial organization. Joining the Company are Joseph Saldanha as Vice President of Marketing and Agustin (Tino) Quintero as Vice P
Read more →MNKDMannKind to Discuss U.S. Commercialization Update for Afrezza
VALENCIA, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host an analyst call for the investment community to learn about the company’s general commercialization strategy in the US for Afrezza® (insulin human) Inhalation Powder. Man
Read more →MNKDMannKind Regains Afrezza Marketing Rights
VALENCIA, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) has assumed responsibility for the worldwide development and commercialization of Afrezza® (insulin human) Inhalation Powder from Sanofi, effective today, in a transition that ensu
Read more →MNKDMatthew J. Pfeffer Chief Executive Officer 661-775-5300 mpfeffer@mannkindcorp.com MANNKIND CORPORATION REPORTS 2015 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Conference Call to Begin Today at 5:00
Chief Executive Officer mpfeffer@mannkindcorp.com MANNKIND CORPORATION REPORTS 2015 FOURTH QUARTER AND FULL YEAR Conference Call to Begin Today at 5:00 PM ET VALENCIA, Calif., March 14, 2016 (GLOBE NEWSWIRE) MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today reported financ
Read more →MNKDMannKind Corporation Reports 2015 Fourth Quarter and Full Year Financial Results
VALENCIA, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2015. For the fourth quarter of 2015, research and development expenses decreased 64.8%, f
Read more →MNKDMannKind Announces Appointment of Michael Castagna as Chief Commercial Officer
VALENCIA, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced that Michael E. Castagna, Pharm.D., has joined the company as its Chief Commercial Officer, effective immediately. Dr. Castagna will lead commercialization efforts
Read more →MNKDMannKind Corporation to Hold 2015 Fourth Quarter and Full Year Financial Results Conference Call on March 14, 2016
VALENCIA, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will release its 2015 fourth quarter and full year financial results on Monday, March 14, 2016 and its management will host a conference call to discuss the fourth quarter and full
Read more →MNKDMannKind to Potentially File 2015 10-K Filing Extension
VALENCIA, Calif., Feb. 26, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced that it anticipates being unable to timely file its Annual Report on Form 10-K for the year ended December 31, 2015 by the filing deadline on February 29, 2016. In s
Read more →MNKDMannKind Mourns the Passing of Chairman Emeritus Alfred E. Mann
VALENCIA, Calif., Feb. 26, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today reported with deep sadness the passing of Alfred E. Mann, age 90, the company’s Chairman Emeritus. Mr. Mann was the Chairman of the Board of MannKind from 2001 until February
Read more →MNKDMannKind Corporation to Present at the RBC Capital Markets 2016 Healthcare Conference
VALENCIA, Calif., Feb. 16, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD), focused on the discovery and development of therapeutic products for diabetes, announced today that it will present at the RBC Capital Markets 2016 Healthcare Conference on Tuesday
Read more →MNKDMannKind Corporation to Hold Investor Conference Call on February 3, 2016
VALENCIA, Calif., Jan. 27, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host a conference call to discuss Company developments at 5:00 PM (Eastern Time) on February 3, 2016. Presenting from the Company will be its Chief Executive Officer, Matthew
Read more →MNKDMannKind Enters Into Collaboration and License Agreement
VALENCIA, Calif., Jan. 21, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced that it has entered into a collaboration and license agreement with a newly formed entity, Receptor Life Sciences, Inc., pursuant to which multiple inhaled therapeut
Read more →MNKDJANUARY 05, 2016 / 4:30PM (EST), MNKD Mannkind Corp Announces Termination of License and Collaboration Agreement With Sanofi Conference Call CORPORATE PARTICIPANTS Matthew Pfeffer MannKind Corporation CFO PRESENTATION Op
JANUARY 05, 2016 / 4:30PM (EST), MNKD Mannkind Corp Announces Termination of License and Collaboration Agreement With Sanofi Conference Call CORPORATE PARTICIPANTS MannKind Corporation CFO Ladies and gentlemen, thank you for standing by. Welcome to MannKind Corporation s mana
Read more →MNKDMannKind Corporation Announces Termination of License and Collaboration Agreement With Sanofi
VALENCIA, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced the termination of its license and collaboration agreement with sanofi-aventis U.S. LLC for the development and commercialization of Afrezza® (insulin human) Inhalat
Read more →MNKDMannKind Corporation to Present at the J.P. Morgan 2016 Healthcare Conference
VALENCIA, Calif., Dec. 29, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD), focused on the discovery and development of therapeutic products for diabetes, announced today that it will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesda
Read more →MNKDMannKind Announces Appointment of Duane DeSisto as Chief Executive Officer
VALENCIA, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) and (TASE:MNKD) today announced the appointment of Duane M. DeSisto as its President and Chief Executive Officer, effective January 5, 2016, replacing Alfred Mann who has served as interim CEO
Read more →MNKDMannKind Announces Senior Management Changes
VALENCIA, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) and (TASE:MNKD) today announced that Hakan Edstrom has stepped down as the President, Chief Executive Officer and as a director of MannKind. The board of directors of MannKind appointed Alfred
Read more →MNKDSTOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this Agreement ) is entered into as of November , 2015 by and between MannKind Corporation, a public corporation incorporated in Delaware, U.S.A (the Company ) and
STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this Agreement ) is entered into as of November , 2015 by and between MannKind Corporation, a public corporation incorporated in Delaware, U.S.A (the Company ) and the undersigned identified on the signature page attached
Read more →MNKDMannKind Announces Pricing of Registered Direct Offering
VALENCIA, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced the pricing of its previously announced registered direct offering of its common stock to selected investment funds in Israel, as well as the total number of shares
Read more →MNKDMannKind Confirms Planned Stock Sale
VALENCIA, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced that its shares will enter the following Tel Aviv Stock Exchange, or TASE, indexes as planned on November 15, 2015: TA-100, TA-75, TA-Composite, TA-Biomed, TA-Blue-T
Read more →MNKDMannKind Corporation Reports 2015 Third Quarter Financial Results
VALENCIA, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today reported financial results for the third quarter ended September 30, 2015. For the three and nine months ended September 30, 2015, product shipments of Afrezza, our novel rapi
Read more →MNKDMannKind Corporation to Hold 2015 Third Quarter Financial Results Conference Call on November 9, 2015
VALENCIA, Calif., Nov. 2, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2015 third quarter financial results on Monday, November 9, 2015 and its management will host a conference call to discuss the third quarter financial results and other Company
Read more →MNKDMannKind Announces Termination of Stock Lending Agreement
VALENCIA, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced the return of 9,000,000 shares of its common stock that were loaned to Bank of America, N.A. pursuant to a stock lending agreement dated August 18, 2010. The stock lending agree
Read more →MNKDMannKind Announces Dual Listing on the Tel Aviv Stock Exchange
VALENCIA, Calif., Oct. 23, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that the Tel Aviv Stock Exchange (TASE) has approved the new listing of MannKind's common shares beginning on October 28, 2015 under the ticker symbol MNKD. Based on the current
Read more →MNKDMannKind to Present at Aegis Capital Corp. 2015 Growth Conference
VALENCIA, Calif., Oct. 5, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at the Aegis Capital Corp. 2015 Growth Conference on Thursday, Oct
Read more →MNKDMANNKIND CORPORATION Common Stock (par value $0.01 per share) Amendment No. 1 to At-The-Market Issuance Sales Agreement
MANNKIND CORPORATION (par value $0.01 per At-The-Market Issuance Sales Agreement Meyers Associates, L.P. (doing business as BP Capital, a division of Meyers Associates, L.P.) 3 Columbus Circle, 15th Floor Ladies and Gentlemen: This Amendment No. 1 to At-The-Market Issuance
Read more →MNKDMannKind Announces Renewal of Shelf Registration and ATM Agreements
VALENCIA, Calif., Sept. 4, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced the renewal of its shelf Registration Statement on Form S-3, as filed with the Securities and Exchange Commission, replacing the previous shelf which expired on August 31, 2015.
Read more →MNKDMannkind Announces Addition of Chief Medical Officer
VALENCIA, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced the appointment of Dr. Raymond Urbanski as its Chief Medical Officer. As Chief Medical Officer, Dr. Urbanski will lead MannKind's overall drug development activities and will be
Read more →MNKDMannKind Corporation Reports 2015 Second Quarter Financial Results
VALENCIA, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the second quarter ended June 30, 2015. For the three and six months ended June 30, 2015, product shipments of Afrezza, our novel rapid-acting inhaled insu
Read more →MNKDMannKind Corporation to Hold 2015 Second Quarter Financial Results Conference Call on August 10, 2015
VALENCIA, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2015 second quarter financial results on Monday, August 10, 2015 and its management will host a conference call to discuss the second quarter financial results and other Company
Read more →MNKDMannKind Triples Production Capacity for Afrezza
VALENCIA, Calif., July 31, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it has completed the validation of two additional filling lines for the manufacture of Afrezza (insulin human) inhalation powder. Material produced during the validation ru
Read more →MNKDMannKind Announces Stock and Note Exchange Agreements with Holders of Outstanding 5.75% Senior Convertible Notes
MannKind Announces Stock and Note Exchange Agreements with Holders of Outstanding 5.75% Senior Convertible Notes Calif., July 29, 2015 (GLOBE NEWSWIRE) MannKind Corporation (the Company or MannKind ) (Nasdaq:MNKD) today announced that it has entered into separate, privately-neg
Read more →MNKDMannKind Corporation Reports 2015 First Quarter Financial Results
VALENCIA, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the first quarter ended March 31, 2015. For the first quarter of 2015, total operating expenses were $21.7 million, a decline of 47.5% compared to the simila
Read more →MNKDMannKind to Present at Bank of America Merrill Lynch 2015 Healthcare Conference
VALENCIA, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at the Bank of America Merrill Lynch 2015 Healthcare Conference on
Read more →MNKDMannKind Corporation to Hold 2015 First Quarter Financial Results Conference Call on May 8, 2015
VALENCIA, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2015 first quarter financial results on Thursday, May 7, 2015 and its management will host a conference call to discuss the first quarter financial results and other Company d
Read more →MNKDMannKind to Manufacture 12 Unit Cartridge Strength of AFREZZA(R) Following FDA Approval
VALENCIA, Calif., April 27, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it will begin to manufacture a 12 unit cartridge strength of AFREZZA (insulin human) Inhalation Powder to improve glycemic control in adult patients with diabetes. The 12
Read more →MNKDMannKind Corporation Reports 2014 Fourth Quarter and Full Year Financial Results
VALENCIA, Calif., Feb. 24, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2014. For the fourth quarter, our operating expenses declined 35% compared to the similar quarter in 20
Read more →MNKDMannKind Corporation to Present at the RBC Capital Markets Global Healthcare Conference
VALENCIA, Calif., Feb. 18, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at the 2015 RBC Capital Markets Global Healthcare Conference on W
Read more →MNKDMannKind Corporation to Hold 2014 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2015
VALENCIA, Calif., Feb. 17, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2014 fourth quarter and full year financial results on Tuesday, February 24, 2015 and its management will host a conference call to discuss the fourth quarter and full year fin
Read more →MNKDMannKind CEO Alfred Mann to Transition to Executive Chairman; COO and President Hakan Edstrom Appointed to CEO
VALENCIA, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a biopharmaceutical-based technology company, today announced that Alfred Mann, the company's founder, retired from his role as Chief Executive Officer effective January 9, 2015 and will trans
Read more →MNKDMannKind Earns $50 Million in Milestone Payments From Sanofi
VALENCIA, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it has earned a total of $50 million in milestone payments in connection with the satisfaction of manufacturing milestones specified in its collaboration and licensing agree
Read more →MNKDMannKind Corporation to Present at the J.P. Morgan 2015 Healthcare Conference
VALENCIA, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at the 33RD Annual J.P. Morgan Healthcare Conference on Wednesday,
Read more →MNKDMannKind Corporation to Present at The 26th Annual Piper Jaffray Healthcare Conference
VALENCIA, Calif., Nov. 25, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at The 26th Annual Piper Jaffray Healthcare Conference on Tuesday
Read more →MNKDMannKind Corporation Reports 2014 Third Quarter Financial Results
VALENCIA, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the third quarter ended September 30, 2014. For the third quarter of 2014, total operating expenses were $38.3 million, compared to $44.8 million for the th
Read more →MNKDMannKind Corporation to Hold 2014 Third Quarter Financial Results Conference Call on November 3, 2014
VALENCIA, Calif., Oct. 27, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2014 third quarter financial results on Monday, November 3, 2014 and its management will host a conference call to discuss the third quarter financial results and other Company
Read more →MNKDExecution Version SENIOR SECURED REVOLVING PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, MannKind Corporation, a Delaware corporation (the Borrower ), hereby unconditionall
SECURED REVOLVING PROMISSORY NOTE FOR VALUE RECEIVED, and subject to the terms and conditions set forth herein, MannKind Corporation, a Delaware corporation (the Borrower ), hereby unconditionally promises to pay to Aventisub LLC, a Delaware limited liability company (the Origi
Read more →MNKDMannKind Announces Receipt of $150 Million Licensing Upfront Payment
VALENCIA, Calif., Sept. 29, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it had received a $150 million upfront payment in connection with an exclusive worldwide collaboration and licensing agreement with Sanofi for development and commercializ
Read more →MNKDMannKind Announces Closing of Global Licensing Agreement With Sanofi
VALENCIA, Calif., Sept. 24, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced the closing of a worldwide exclusive collaboration and licensing agreement with Sanofi for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new
Read more →MNKDMannKind Corporation to Present at Morgan Stanley Global Healthcare Conference
VALENCIA, Calif., Sept. 2, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at The Morgan Stanley Global Healthcare Conference on Tuesday, Se
Read more →MNKDMannKind Corporation Reports 2014 Second Quarter Financial Results
VALENCIA, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the second quarter ended June 30, 2014. For the second quarter of 2014, total operating expenses were $69.8 million, compared to $41.6 million for the seco
Read more →MNKDMannKind Corporation to Hold 2014 Second Quarter Financial Results Conference Call on August 11, 2014
VALENCIA, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2014 second quarter financial results on Monday, August 11, 2014 and its management will host a conference call to discuss the second quarter financial results and other Company
Read more →MNKDMannKind Corporation Announces FDA Approval of AFREZZA ; A Novel, Rapid-Acting Inhaled Insulin for the Treatment of Diabetes VALENCIA, CA
MannKind Corporation Announces FDA Approval of AFREZZA ; A Novel, Rapid-Acting Inhaled Insulin for the Treatment of Diabetes VALENCIA, CA June 27, 2014 MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Food & Drug Administration (FDA) has approved AFREZZA (insu
Read more →MNKDMannKind Corporation Reports 2014 First Quarter Financial Results
VALENCIA, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, total operating expenses were $41.4 million, compared to $36.4 million for the first
Read more →MNKDMannKind to Present at Bank of America Merrill Lynch 2014 Health Care Conference
VALENCIA, Calif., May 7, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday
Read more →MNKDMannKind Corporation to Hold 2014 First Quarter Financial Results Conference Call on May 12, 2014
VALENCIA, Calif., May 5, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2014 first quarter financial results on Monday, May 12, 2014 and its management will host a conference call to discuss the first quarter financial results and other Company devel
Read more →MNKDMannKind Updates Status of New Drug Application for AFREZZA(R)
VALENCIA, Calif., April 7, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA by three months to July 15, 2014 in order to provide ti
Read more →MNKDMannKind Corporation Reports 2013 Fourth Quarter and Full Year Financial Results
VALENCIA, Calif., Feb. 18, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2013. For the fourth quarter of 2013, total operating expenses were $46.6 million, compared to $33.5 mi
Read more →MNKDMannKind Corporation to Hold 2013 Fourth Quarter and Full Year Financial Results Conference Call on February 18, 2014
VALENCIA, Calif., Feb. 4, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2013 fourth quarter and full year financial results on Tuesday, February 18, 2014 and its management will host a conference call to discuss the fourth quarter and full year fina
Read more →MNKDMannKind Announces Tentative Date of FDA Advisory Committee Review of AFREZZA
VALENCIA, Calif., Jan. 10, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is tentatively scheduled on April 1, 2014 to review MannKind's New
Read more →MNKDMannKind Corporation to Present at the J.P. Morgan 2014 Healthcare Conference
VALENCIA, Calif., Jan. 8, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at the J.P. Morgan 2014 Healthcare Conference on Wednesday, January 15, 2014
Read more →MNKDMannKind Corporation Reports 2013 Third Quarter Financial Results - Conference Call to Begin Today at 5:00 PM ET - VALENCIA, Calif.--(BUSINESS WIRE)
Corporation Reports 2013 Third Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET - VALENCIA, Calif.--(BUSINESS WIRE)--November 4, 2013--MannKind Corporation (Nasdaq:MNKD) today reported financial results for the third quarter ended September 30, 2013. Fo
Read more →MNKDA CKNOWLEDGEMENT AND A GREEMENT This Acknowledgment and Agreement (this Agreement ) is made as of
ACKNOWLEDGEMENT AND AGREEMENT This Acknowledgment and Agreement (this Agreement ) is made as of October 31, 2013 (the Effective Date ), by and between MANNKIND CORPORATION, a Delaware corporation (the Company ), and THE MANN GROUP LLC ( The Mann Group ). WHEREAS, The Mann Gro
Read more →MNKDMannKind Announces FDA Acknowledgement of Resubmission of New Drug Application for AFREZZA VALENCIA, Calif.--(BUSINESS WIRE)
Announces FDA Acknowledgement of Resubmission of New Drug Application VALENCIA, Calif.--(BUSINESS WIRE)--October 30, 2013--MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Appl
Read more →MNKDMatthew Pfeffer Chief Financial Officer 661 775-5300 mpfeffer@mannkindcorp.com Media Inquiries: Laura De Zutter or Jeff Hoyak MCS Healthcare Public Relations 800 477-9626 jeffh@mcspr.com laurad@mcspr.com
Chief Financial Officer mpfeffer@mannkindcorp.com Laura De Zutter or Jeff Hoyak MCS Healthcare Public Relations MannKind Resubmits New Drug Application to U.S. FDA for AFREZZA for the Treatment of Adults with Diabetes VALENCIA, California (Business Wire) October 14, 2013 M
Read more →MNKDFrequently Asked Questions about the Affinity 1 and Affinity 2 Trials i (
Frequently Asked Questions about the The recently completed Affinity trials were designed specifically to address the issues raised by the FDA in their complete response letters. In designing the Affinity trials we had multiple meetings with the agency to get their input and cl
Read more →MNKDAUGUST 14, 2013 / 8:00PM, MNKD - Q2 2013 MannKind Earnings & Clinical Trial Results Conference Call CORPORATE PARTICIPANTS Matthew Pfeffer MannKind Corporation - CFO Hakan Edstrom MannKind Corporation - President & COO R
CORPORATE PARTICIPANTS Matthew Pfeffer MannKind Corporation - CFO Hakan Edstrom MannKind Corporation - President & COO Baughman MannKind Corporation - SVP - Clinical Sciences Alfred Mann MannKind Corporation - Chairman of the Board and CONFERENCE CALL PARTICIPANTS Simos Sim
Read more →MNKDMatthew Pfeffer Chief Financial Officer 661 775-5300 mpfeffer@mannkindcorp.com MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes VALENCIA, Californi
Chief Financial Officer mpfeffer@mannkindcorp.com MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes VALENCIA, California (Business Wire) August 14, 2013 MannKind Corporation (Nasdaq: MNKD) today announced positive prelimi
Read more →MNKDE XECUTION V ERSION FACILITY AGREEMENT (this Agreement ), dated as of
FACILITY AGREEMENT (this Agreement ), dated as of July 1, 2013, between MannKind Corporation, a Delaware corporation (the Borrower ), and the purchasers set forth on the signature page of this Agreement (the Purchasers , and together with the Borrower, the Parties ). W I T N E
Read more →MNKDMannKind Corporation Reports 2013 First Quarter Financial Results - Conference Call to Begin Today at 5:00 P.M. EDT - VALENCIA, Calif.--(BUSINESS WIRE)
Corporation Reports 2013 First Quarter Financial Results Conference Call to Begin Today at 5:00 P.M. EDT - VALENCIA, Calif.--(BUSINESS WIRE)--May 9, 2013--MannKind Corporation (Nasdaq: MNKD) today reported financial results for the first quarter ended March 31, 2013. For the
Read more →Competitive Position
How MNKD ranks across every disease it competes inCompetitive Position is a premium feature
See how MNKD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial